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8 
INTRODUCTION 
                              
 Diabetes is truly the most challenging health problem in this 21
st
 century.
(1)
Type 2 
Diabetes Mellitus is rapidly emerging as a modern epidemic
(2) 
both in high income and low 
income countries. It is stated as a world public health problem and the global crisis due to 
diabetes threatens the health as well as the economy of every nation. The good news is, once 
the risk factors are identified the development of Type 2 Diabetes can be either delayed or 
even prevented by healthy lifestyle pattern and required medications. The goal is to reduce the 
disease and its economic burden and improve the quality of life for all persons who have, or 
are at risk of, Diabetes Mellitus.  
 
 The Greek Apollonius of Memphi first used the term "diabetes" or "to pass through" in 
230 BC
(146)
. The Indian physicians, Sushruta and Charaka were the first to identify Type 1 and 
Type 2 Diabetes as two separate conditions in 400-500 AD
(146)
. In the late 17
th
 century, the 
Britain John Rolle added the term "mellitus" or "from honey" to separate the condition from 
Diabetes Insipidus
(146)
. 
 
 Type 2 Diabetes is a multisystem disorder due to defect in glucose metabolism causes  
multiple metabolic abnormalities manifesting in varying degrees. The glucose metabolism is 
well controlled by multiple hormones and neurotransmitters in response to nutritional, 
emotional and environmental changes. Unger first described diabetes, as a “bi-hormonal”  
disease characterized by insulin deficiency and glucagon excess
(3)
.                                
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 The multi-hormonal view of glucose homeostasis through the pancreatic and incretin  
hormones let to a new understanding of Diabetes Mellitus
(3)
. The glucoregulatory hormones  
included are insulin, glucagon, amylin, glucagon like peptide-1, glucose–dependent  
insulinotropic peptide, epinephrine, cortisol and growth hormones
(3)
.   
 
 Traditionally the pathophysiology of T2DM was focused on beta cell dysfunction and  
insulin resistance in liver and skeletal muscle. Now after many researches in the past two  
decades, revealed a basic understanding about mechanism and dysfunctions in  
gastrointestinal  tract, pancreatic alpha cells, adipose tissue, brain and kidney that produced  
more robust picture of Type 2 Diabetes 
(4)
.    
 
Despite the  best  efforts  of   intensively  managing  diabetes  with   insulin  and   
antihyperglycemic  drugs, there  were  unpredictable  glucose  fluctuations, hypoglycemia  
and  weight  gain leading  to  frustration  and  risk.  Universally, World Health Organization 
(WHO) and American Diabetes Association (ADA) criteria are still used for screening and 
diagnosis.                 
 
 Recent research into the pathophysiology of Type 2 Diabetes has led to the 
introduction of new medications like inhibitors of the sodium-glucose cotransporter 2 and 
11ß-hydroxysteroid dehydrogenase 1, insulin-releasing glucokinase activators and pancreatic-
G-protein-coupled fatty-acid-receptor agonists, glucagon like peptide-1 analogues,  
dipeptidyl peptidase-IV inhibitors, metabolic inhibitors of hepatic glucose output, glucagon-
receptor antagonists and quick-release bromocriptine 
(5)
. 
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Even after the invention of many new drugs, the prevalence of Type 2 Diabetes is  
still in the higher end. According to International Diabetic Federation 2014, nearly 183 million 
people are still unaware that they are living with diabetes
(17)
. Therefore, the identification of 
individuals at high risk of getting diabetes is of great importance for investigators and health 
care providers.  
 
Type 2 Diabetes being a multi-factorial genetic syndrome and the advancing   
genotyping technology in the last 5years, have facilitated rapid progress in genetic studies in 
T2DM. Since 2007, more than 65 genetic variants have been identified by Genome-Wide 
Association Studies (GWAS). They were found to increase the risk of T2DM by 10–30%
(6)
. 
Most of these variants are non-coding variants, and identifying their functional consequences 
is a real challenge to investigators. Many of the variants identified are involved in the 
regulation of insulin secretion and not insulin action in insulin-sensitive tissues. However, 
how genetics involve in the development of diabetes is poorly understood. 
 
The major issue to address in Diabetes biology is to identify the genetic changes in the 
disease and their occurrence in different populations. Variants of a number of genes have been 
associated to T2DM among Europeans. However, the contributions of these genetic variants 
in other ethnic groups are unclear. Reports from several Indian populations give a 
heterogeneous picture owing to its diverse ethnicity. 
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A large amount of data available on the genetics of T2DM from association  studies of 
candidate gene variation include variants of : 
 
1. Calpain-10 -CAPN10, Horikawa et al 
(7)
 ., 
 
2. Peroxisome proliferator-activated  receptor  gamma -PPARG, Agostini et al 
(8) 
3. Potassium inwardly rectifying channel, subfamily J, member 11-KCNJ11, Florez 
et al., 
 
4. ATP binding  cassette, subfamilyC, member 8  - ABCC8, Van Dam RM et al .,
 
5. Hepatocyte nuclear factor-1A - HNF1A, Triggs et al., 
 
6. Hepatocyte nuclear factor-4A  - HNF4A, Muller et al., 
 
7. Glucokinase –GCK, Weedon et al., 
 
8. Plasma cell glycoprotein1/encoding ectonucleotide pyrophosphate 
phosphodiesterase 1 -PC-1/ENPPI, Bottcher  et al.,
 
9. Insulin receptor substrate-1 -IRS-1, Hitman et al.,
 
10. Protein tyrosine phosphatase 1B –PTPNI, Florez et al., 
 
11. The nuclear lamina gene-LMNA,Owen et al.,
 
12. Transcription factor 7-like 2 -TCF7L2, Grant et al.,  
 
13. Insulin like growth factor 2 mRNA binding protein 2 -IGF2BP2, Zeggeni et al., 
 
14. KQT like subfamily, member 1 gene-KCNQ1,Tan et al., 
(9). 
 
Among all the association studies with T2DM in various populations including Indian 
populations, TCF7L2 has been shown to be most promising in South Indian ,Bodhini et al.,
(10)
 
and Western Indian, Chandak et al.,
(11)
 populations, where intronic SNP (rs7903146, 
rs12255372, rs4506565) show association with T2DM.
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TCF7L2 gene , a  transcription  factor   is  critical  for  expression  of   
glucagon like peptide-1, an  incretin  hormone  in  intestinal  endocrine  cells  that  mediates  
insulin  synthesis  and  secretion  in  β cells  of  pancreas 
(12)
, β cell proliferation, neogenesis  
and  protection  against  apoptosis.
 
                     
Hence  it  is  proposed  to  study  the  association  of  TCF7L2  gene  polymorphism  
with  Type 2 Diabetes  and  also  to  correlate  with  GLP-1  level  and  insulin  level . 
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AIM OF THE STUDY 
 
Glucagon like peptide-1 has significant role in endocrine pancreatic hormone  
secretion through the enteroinsulinar axis. The transcription factor TCF7L2 is an important  
mediator for the Proglucagon gene transcription and GLP-1 production.  
With these salient mechanisms in Insulin secretion and maintenance of glucose  
homeostasis, the aim of this study is to find an association: 
1. Between TCF7L2 gene polymorphism at two restriction sites and Type 2 Diabetes 
Mellitus in cases and controls. 
2. Between postprandial GLP-1 level in circulation and TCF7L2 gene polymorphism. 
3. Between Insulin, HbA1c and Glucose level in blood and TCF7L2 gene polymorphism. 
4. Between TCF7L2 gene – T allele and its associated risk of Type 2 Diabetes. 
5. Between T allele and GLP-1 level in blood in cases and controls. 
6. By  logistic  regression  to  assess  the  individual  predictability  of  various  risk  factors  
for  the development of Type 2 Diabetes  Mellitus.   
7. To study  the  distribution  of  risk  T  allele  of  TCF7L2  gene  in  the  study  population. 
14 
 
REVIEW OF LITERATURE 
 
Diabetes  is  defined  as  a  metabolic  disorder  due  to  heterogeneous  etiology  which  
presents  with  chronic  hyperglycemia  along  with  disturbances  in  all  three  macro 
molecules  carbohydrate,  protein,  lipid  metabolism  where  the  major  defect  can  be  in  
insulin  secretion, insulin  action or both
(13)
. Degree  of  hyperglycemia  is  the  main  
determinant  for development  of  complications  like  diabetic  retinopathy, diabetic  
nephropathy  and  diabetic  neuropathy.  In  recent  trend  children, adolescents  and  young  
adults  are  becoming  the  target  for  Type 2 diabetes  and  pre diabetes,  in  many countries  
including  Japan, USA, India, Australia and UK, Bloomgarden et al., .The  decrease  in  the  
age  of  onset  of Diabetes is  of  great  concern, as the  main  burden is  on  future generations. 
 
The  cause  for  diabetes  is  enclosed  in  a  complex  group  of  genetic  and  
epigenetic  systems  and  its  interaction   with  equitably  complex environmental  and  
behavioral  factors 
(14)
. Diabetes Mellitus is an ambulatory   “care sensitive condition” 
(15)
. The  
consequences of  diabetes are, it  reduces  life  expectancy  by nearly 15 years, it  increases  
the  risk  of  CVD  by  2 to 4 times, and for kidney  failure, lower limb  amputations, adult – 
onset blindness, Diabetes is the leading cause. In  addition  to  these  human  cost, the  costs of  
medical  care, disability ,and  premature  death  increase  the  financial  cost  due  to  type 2 
diabetes.  
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Epidemiology: 
Diabetes  mellitus  is  the  most  important  health  challenge  to  all  nations  that  is  
increasing in an  alarming  rate  all  over  the  world 
(14)
. The  Prevalence  of  Type 2 Diabetes   
was  around  171  million    in  2000, which  has  almost  doubled  in  past  decades 
.According  to  the  International  Diabetes  Federation(IDF) –sixth  diabetic  atlas
(147)
, the 
World  diabetic  prevalence  in  2013  is  estimated  to  be  382 million   and  is  expected  to  
increase   to  592  million  by  2035  where  the rate  of  increase is  55%. Nearly  175 million  
people are currently  undiagnosed  and  unknowingly  progressing  towards  complications. 
The  estimated  rate  of  increase  in  prevalence  was  69%  in  developing  countries  and  
20%  in  developed  countries 
(17).
 This  shows  the  growing  burden  of  diabetes  in   
developing  countries  like  India.  According  to  IDF –  number  of  individuals with  Type 2 
Diabetes in  2013  are  - China – 98.4 million , India -65.1 million  and United states – 24.4 
million, showing  the  largest  number  of  diabetic  population  in  the  world. 
 
  In  India,  Type 2 Diabetes  is erupting  like  a  Pandemic. IDF  estimated  that the  
total  number  of  diabetic  subjects  to  be  around  50.8  million  in  2010  and  expected  to  
rise  to  87 million   by  2030 
(18)
. In  India, people  both in rural  and  urban  regions  were  
affected  by  diabetes, but  Urban  India  has  a  higher  prevalence  of  5.6%  than   Rural  
India  with  2.7% 
(19)
. The  high  prevalence  observed  in  urban  area  shows  that  the  rapid  
urbanization   plays a major  role. The  most  worrying  trend  in  incidence  of  diabetes  is  its  
shift   towards  younger  age  where  Diabetes  commences   ten  years  earlier  than   in  
western  countries
(20)
. In Chennai,  diabetic  prevalence was 13.5% in 2000 that  went up  to  
14.3%  in  2004  and  reached   18.6%  in  2006 
(20).
 The primary cause for the epidemic of  
16 
 
INTERNATIONAL DIABETIC FEDERATION 2014 
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diabetes is the rapid transition of culture associated with dietary changes and  physical 
inactivity which are evident from the increased diabetic  prevalence in the urban population 
like  Chennai. 
 
Classification: 
 ADA   gave  the  detailed  classification  for   diabetes  based  on  etiology  that  was  
published  in  the  year 2014. 
Diabetes Mellitus - Etiologically classified into four categories  
(22) 
: 
I. Type 1 Diabetes (usually show absolute insulin deficiency due to β cell destruction). 
                A. Immune mediated. 
                B. Idiopathic. 
 
II. Type 2 Diabetes(caused mainly by insulin resistance along relative insulin  
                             deficiency or by insulin secretory defect along with insulin resistance) 
 
III. Other Types 
 
A. Genetic  and  Epigenetic  defects  of  β- cells 
       1. Chromosome 12, HNF-1a (MODY3) 
       2. Chromosome 7, glucokinase (MODY2) 
       3. Chromosome 20, HNF-4a (MODY1) 
       4. Chromosome 13, insulin promoter factor-1 (IPF-1; MODY4) 
       5. Chromosome 17, HNF-1b (MODY5) 
       6. Chromosome 2, NeuroD1 (MODY6) 
       7. Mitochondrial DNA 
       8.Others 
 
18 
B. Genetic defects in insulin action 
C. Diseases of the exocrine pancreas 
D. Endocrinopathies 
E. Drug or chemical induced 
F. Infections 
G. Uncommon forms of immune-mediated diabetes 
H. Other genetic syndromes sometimes associated with diabetes 
 
IV. Gestational diabetes mellitus. 
 
  Disorders  of  Glycemia  : Etiological  category and  stages:
(21) 
1. Normoglycemia:   
Regulated  normal blood glucose level. 
2. Hyperglycemia  in  Prediabetic  stage: 
 Includes impaired glucose  tolerance  and  impaired  fasting  glucose . 
3. Hyperglycemia  with  Frank  diabetic  stage: 
High blood glucose level – unregulated. 
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Among  the  various  types  of  diabetes, Type 2 Diabetes  accounts  for   90% to 95%  
of  diabetic  cases  and  Type 1 Diabetes  accounts  for  5%-10%  only
(21)
.  
Type 1 Diabetes  Mellitus: 
Type  1 diabetes  is  immune  mediated disorder  ,also known  as  insulin  dependent  
diabetes  or  juvenile  onset  diabetes. Prevalence  of  type 1  diabetes  was  found  to  be  less  
than  1%  in  most   population.  But  the  worldwide  increase  in  incidence  of  Type 1 
Diabetes  was at  a  rate  of  3%  per  year  (Onkamo et al., 1999)(21). Holt, 2004  estimated  that  
nearly  20  million  people  worldwide, were  affected  by  type 1 diabetes.The incidence of 
Type 1 Diabetes was more  among  childhood and adolescent  age  groups,  but  was  also  
found  in late eighties and nineties
(21)
.   
 
There  is  destruction  of  beta  cells  of  pancreas  due to cell  mediated  autoimmune 
reaction. The  auto antibodies  are  found  against  Islet cells,  Insulin,  Glutamic  Acid  
Decarboxylase (GAD) and Trypsin IA-2 & IA2β . In 85 to 90 %  of  diabetic  cases , one and 
mostly more of these  autoantibodies are  present. The  proven  genetic  causes  for   Type 1 
Diabetes  are  strongly   HLA  associated  with  linkage  to  DQA  and  DQB genes. A  recent  
study  by Dotman  et  al., showed  a  distinct  seasonal  variation  in  incidence  of  Type 1  
Diabetes  in various  countries  with  higher  rates  in  cold  winter  season  and  lower  rates  
in  warm  summer  months.
(22)
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Risk  factors : 
Among  various  environmental  risk  factors  of  Type 1 DM, changing  global  
environment  points  out  an  important   reason  for  recent  temporal  increase  of  type 1 DM  
incidence. Other  environmental  risk  factors  for  type 1 DM  that  has  received  more  
attention  recently  are  viruses  and  infant  nutrition. Various  viral  infections   that  increase  
the  subsequent  risk  of  developing  Type 1 Diabetes  are  Coxsackie virus B (Dahlquist et 
al., 1998), rotavirus (Honeyman et al., 2000), cytomegalovirus (Pak et al., 1988),mumps 
(Hyoty et al., 1993) and rubella.T1D  children  were  found   being  breast  fed  for  shorter  
period  of  time  than  non  diabetic  children (Borsh-Johnsen et al., 1984)
(22)
   
 
Type 1 Diabetes, a chronic T-cell mediated  autoimmune disease that causes 
destruction of  pancreatic  beta –cells  leading  to  progressive  and  irreversible  failure  of  
insulin  secretion. Type 1 diabetes mostly  presents  with diabetic ketoacidosis (DKA). Due  to  
lack  of  insulin, rate of  glycogenolysis  and  gluconeogenesis  in the  liver  is  increased   
leading   to high   glucose  concentration. This  causes  osmotic  diuresis  with  symptoms  of  
polyuria, polydypsia  and  polyphagia. Lack  of  insulin  causes  increased   lipolysis  in  
adipose  tissue  and  accumulation  of  ketone  bodies  progressing  to  diabetic  ketoacidosis.  
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According  to  The  American  Diabetes  Association’s  (ADA ) 2014 
(22)
 : 
Plasma blood glucose and A1C goals for type 1 diabetes by age-group 
 
Values by age 
(years) 
Plasma blood glucose goal range(mg/dL)                       
Rationale 
 
Before 
meals 
Bedtime/overnight A1C 
Toddlers and 
preschoolers (0–6) 
100–180 110–200 , <8.5% -Vulnerabilityt hypoglycemia -
Insulin sensitivity 
-Unpredictability in dietary 
intake and physical activity  
-A lower goal (<8.0%) is                                                                                                      
reasonable if it achieved 
without excessive                                      
hypoglycemia 
School age (6–12)   90–180 100–180 <8% -Vulnerability of hypoglycemia                                                                                     
- A lower goal (<7.5%) is                                                                                                                      
reasonable if it can be achieved                                                                                       
without excessive 
hypoglycemia 
Adolescents and   90–130 90–150 <7.5%    -A lower goal (<7.0%) is                                                                                                      
reasonable if it can be achieved                                                                                             
young adults (13–19) without                                                                     
excessive hypoglycemia 
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Type 2  Diabetes Mellitus : 
Type 2 Diabetes Mellitus also  referred  as  non  insulin  dependent  diabetes  or  adult  
onset diabetes  that   shows  chiefly  insulin  resistance   along  with  relative  rather  than  
absolute  insulin  deficiency. The  specific  etiology  of  this  type  of  diabetes  is  not  known. 
Initially  with  beta  cell  functions   being  normal, the  insulin  resistant  patients  show  high  
blood  glucose  level  with  insulin  level  appearing  normal,  and  later   the  insulin   
secretion  becomes  defective  and  inability to  compensate  for  the  insulin   resistance.  As  
majority  of  Type 2 Diabetics  are  obese,  Obesity  itself  could be a cause for insulin  
resistance.  Obesity due to  increased  abdominal  fat   predominantly  contributes  to  insulin  
resistance  than  the  traditional  weight  criteria,  leading  to  Type 2 Diabetes. The  
presentation  of  Type 2 Diabetes  is  extremely  critical  and  tricky.  Most  of  the  time 
T2DM  remains  undiagnosed  for  years  with  hyperglycemic  blood  status  without  any  
classical  symptoms. It  seldom  presents  with   ketoacidosis  unless  there  is  stress  of  
illness  such  as  infections. But  the  inexorable  risk  of T2DM  patients  is  development  of   
micro  and  macro  vascular  complications 
(21)
. 
 Diagnostic Criteria : 
ADA-  Standards  of  Care  stated  the  following  diagnostic  criteria   for  Type 2 
Diabetes in  2014 :
(22)
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 ADA  -  2014  -  Criteria for the diagnosis of  diabetes 
                                                  
 
 
  A1C > 6.5%.  
The test should be performed  in a laboratory using a method that is  NGSP certified and 
standardized  to the  DCCT assay.* 
OR 
  FPG >126 mg/dL (7.0 mmol/L).  
  Fasting is defined as no caloric intake for at least 8 h.* 
OR 
 Two-hour PG >200 mg/dL (11.1 mmol/L)  during an OGTT.  
The test should be  performed as  described by the WHO, using a glucose load containing 
the equivalent of 75 g anhydrous glucose dissolved in water.* 
OR 
 In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis,  
a random plasma glucose > 200 mg/dL (11.1 mmol/L). 
 
                                                
                                                                                                                                                                                                                                                                             
An  International  expert  committee  on  Diagnosis  and  Classification of  Diabetes  
Mellitus  did  extensive  review  and  included  HbA1c in  diagnostic  criteria   that   must  be  
measured  using  the  method  that  is  certified  by  National  Glycohemoglobin  
Standardisation  Program  (NGSP) and  results  must  be  tracable  to  the  Diabetic  Control  
and  Complications  Trial  (DCCT) reference assay.
(22)
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The  Expert  Committee  on  Diagnosis  and  Classification  of  Diabetes  Mellitus  
gave  the  criteria  for Increased  risk  for  Diabetes  category  -  Pre Diabetics
(22)
: 
 
1. Fasting  plasma  glucose  100 – 125 mg/dl ( 5.6 – 6.9 mmol/L) 
 
       Stated  as  Impaired  Fasting  glucose ( IFG ). 
 
                                                             or 
 
2. Two  hours  Plasma  Glucose  in  the  75-gms  OGTT 
 
140 – 199 mg/dl ( 7.8 – 11.0  mmol/L) 
 
   Stated  as  Impaired  Glucose  Tolerance  (IGT) 
 
 
                                                         or 
 
3. A1C  5.7-6.4 % 
 
 
Risk  factors : 
The   risk  factors  for  Type 2 diabetes  are classified as: 
1. non modifiable (genetic)  and  
2. modifiable  (environmental)  risk  factors 
Non  modifiable Risk  factors: 
1. Age: 
The  chances  of  developing  diabetes  was  found  to  be  extremely  high  after  forty  
years  of  age. 
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2. Race,  Ethnicity  and  Family  history :  
Many  inherited  genetic  factors  were  identified  that  exposes  certain  ethnic  groups  
with  high  chances  of  developing   diabetes .(Asians,  Africans, Alaskan natives, American 
Indians, Hispanic Americans, Pacific islanders descend). 
Modifiable Risk factors: 
1. Obesity: 
To  estimate  body  fat  and  its  distribution  Body  Mass  Index, Waist  circumference 
and  Waist  hip  ratio  are  measured  which  are  the  health  risks  for  developing  diabetes. 
Evidences  show  obesity  as  the  major  drive  of  Type 2 Diabetes 
(24)
.Ectopic  fat  deposits  
leads   to  hepatic  insulin  resistance  which is found  to  precede  Type 2 Diabetes  
manifestation
(24)
.   
2. Dyslipidemia: 
Recent  researches  showed   two  to  four  times  increased  risk  of  getting  CAD  in 
diabetic  subjects 
(23)
 .CAD  was  prevalent  more  in  those  diabetic  patients  with  isolated   
high  cholesterol,  high  LDL  and  low  HDL 
(25) 
.     
3. Hypertension: 
In  Hypertensive  subjects  the  risk  of  diabetes  is  2.5  times  more   than  in  
normotensive  subjects. 
4. Dietary habits: 
Dietary  fibres  is  one  of  many  factors  that  affect  post  prandial  glucose  and  
insulin  receptor. An  inverse  relationship  is  found  between  blood  insulin  levels  and  
dietary  fibres 
(27)
. Diet  rich  in  non starch  polysaccharides , ώ-3 fatty  acids , low  glycemic   
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index  foods , micronutrients  like  vitamin E, chromium,  magnesium  decrease  the  risk  of  
Type 2 Diabetes.
(26) 
 
Type 2 Diabetes  has  strong  genetic reason. However  the  genetics  of diabetes  is  
complex  and  yet  to  be  clearly  defined. The  cause  for  inability  of  pancreas  to  secrete  
enough  insulin  or  insulin  produced  showing  resistance  would  ultimately  be  genetic 
(non-modifiable  risk  factor ) but  not  every  person  who  has  that  particular  genetic  
abnormality  will  develop  Type 2 Diabetes  as  other  risk  factors  along  with  life style  
choices (modifiable  risk  factors)  have  great  influence  on  it.  Even  for  those  having  
strong  family  history  or  belonging  to  certain  ethnic  groups  with  inheritable  risk  factors  
for   Type 2 Diabetes, the  disorder   may or  may  not  manifest   depending on  their  lifestyle  
pattern  and   environmental  factors. By  following  healthy  lifestyle  pattern  like  increased  
physical  activity,  regular  exercise  and  taking  balanced   diet  have  showed   nearly  60%  
decrease  in  risk  of  progression  of   IGT  to  T2D  in  contrast  to  nearly  30%  reduction  in  
risk  of  progression  to T2D  by  taking  oral  hypoglycemic  drugs (Diabetes Prevention 
Program Study Group, 2002, US). Diet  and  physical  activity  play  critical  role  in  the  
management  of (ABC) A1c, Blood  pressure, Cholesterol  in  Type  2  Diabetic  patients. 
Thus  the  metabolic  pathway  of  macro  and  micro  molecules  ingested  in  diet  has  to  be  
under  strict  regulation. 
 
Pathophysiology   behind  Diabetes : 
 
Diabetes  is  a  metabolic  disorder   with  chronic  hyperglycemia  and  the  major  
defect  is  found  in  the  metabolic  pathway  of  carbohydrate  which constitutes  the  major  
part  of  physiological  system. Carbohydrates  are  not  only  major  energy  providers  but   
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also  needed  for  specific  cellular  functions  and  protein  modifications  like  glycosylation. 
Hence it  is  highly  essential   for  the  body   to  maintain  the   blood  glucose  levels  within   
limits  which  is  done  by  many  hormones  of   which  the  most  significant  action  is  
exerted  by  the  hormone  Insulin . 
Among  various  monosaccharides, Glucose  absorbed  from  the  diet  acts  as  the  
major  signals  to  endocrine  pancreas  for  secretion  of  Insulin, the chief  hormone  involved  
in  energy  homeostasis  (glucose homeostasis). Glucose  along  with  certain  lipids  and  
proteins  also stimulate, enteroendocrine K cells  and  L cells  in  the  intestine  to  secrete  
incretins -   the  peptide  hormones , Glucose - dependent  Insulinotropic  Polypeptide (GIP) 
and Glucagon - Like  Peptide-1 (GLP-1 )  respectively. These incretin hormones play 
important role in glucose homeostasis. 
The  arrival  of  macronutrients  in  the  gut  are  sensed  by, similar  molecular  sensors  
in  K  and  L  cells. The electroneutral  uptake  of  nutrients are metabolized, increasing  
cytosolic  ATP  which   closes  ATP  sensitive  K channels leading to depolarization of  cell 
membrane. As  the   calcium dependant voltage channels  are  opened, cytosolic  Ca
2+
 levels  
are  elevated  resulting  in  incretin  hormone  release
(96)
.  Nutrients also  interact  with  cell  
surface  sensors  without  entering   the  cell and  triggers  hormone  release 
(56)
. (Fig:1) 
 
There  are  many gut  factors and hormones  that  leads  to  enhanced  insulin  secretion   
after  a  meal and  they constitute  ,Enteroinsulinar  axis, which  was  first  coined  by  Ungar  
and  Eisentraut -1969
(40,41) .
They   maintain  the glucose  homeostasis  by  modulating  the   
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hormonal  output  of  endocrine  pancreas   against  the  circulating  blood  glucose  
concentration  via  the  neural,  hormonal  and  the  circulating  nutrient  metabolites . 
Fig 1 : Release of Incretin Hormones in GIT 
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Neural  component  of  enteroinsulinar  axis:      
Neural  component  is  said to  have  a  significant  role  though  little  is  known  about  
it. Pancreatic  exocrine  and  endocrine  cells  are  subject  to  cholinergic,  adrenergic  and  
peptidergic  innervations. Cholinergic  innervations  is  responsible  for  “ cephalic  phase ” of  
insulin  release  that   is  independent  of  nutrients  absorbed where it  regulates  basal  insulin  
secretion  and  postprandial  insulin  secretion   (Ahren et al. 1986)
(57)
. Peptidergic   neurons  
that  innervate  pancreas  contains  gut  peptides  like  VIP-Vasoactive intestinal  peptide  and  
CCK-cholecystokinin  acts  as  neurotransmitter  for  insulin  secretion  but  its  precise  role  
is not  eluded.  
Nutrient components  on  enteroinsulinar  axis: 
The  only  dietary  sugar, to  stimulate  insulin  secretion  through  enteroinsulinar  axis  
is  Glucose. Glucose  also  has  a  crutial  role  in  modulating  insulinotropic  potency  of   
other  stimulators  on  pancreas  to  exert  its  action
(57)
. Of  the  several  amino  acids  that  
shows  direct  effect  on  pancreatic  islet  cells, arginine, lysine  and  leucine  are  found  to  
be  most  potent  stimulators
(57)
. A  modest  stimulatory  effect  is  exerted  on  β-cells  of  
pancreas  by  certain  fatty  acids  and  ketone  bodies  in  the  presence  of  Glucose (Gerich et 
al)
(57)
. 
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Hormonal  component  of  enteroinsulinar  axis: 
The  intestinally  derived  incretins,  GLP-1  and  GIP  are  the two  major  relevant 
insulinotropic incretin hormones
(42) 
that constitutes the hormonal component of 
enteroinsulinar  axis. 
Action  of   Glucose - dependent  Insulinotropic  Polypeptide (GIP): 
GIP  exerts  glucose  dependant  stimulatory  effect  on  insulin  secretion   in  β cells  
of   pancreas and a  prompt  insulin   mediated  uptake  of  glucose  in  various  tissues. It  is  
also  found  to  inhibit   gastric  acid  secretion  and  gastrointestinal  motility  at   
supraphysiological  doses (Brown et al., 1975)(58). 
Action  of  Glucagon like peptide -1   (GLP-1) :          
The  incretin  hormone  GLP-1  carry   signals  for  pancreatic  function,  gastric 
emptying,  intestinal motility  and  food   intake (Willms et al., 1996). It  exerts  a  potential  
insulinotropic  effect  by  stimulating  glucose  dependant  insulin  secretion  in  β cells  of  
pancreas.  GLP-1 incretin consequentially  regulates  synthesis  and  secretion  of  insulin  and  
glucagon  in  pancreatic  islet  cells. A  proper  ratio  of  insulin  to  glucagon is  found to be 
regulated by GLP-1, which  is  essential  for  the  regulation  of  carbohydrate  metabolism  
and  maintain  glucose  homeostasis. The  ratio   increases  in  postprandial   state  favoring  
anabolism  and  decreases  in  fasting  state  favoring  catabolism.   
 Thus, after the  digestion  of  macro  and  micro  molecules  in  the  diet,  the  major  
monosaccharide – glucose  along  gut  hormones, signals  pancreas  for  insulin  secretion  and    
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regulates  carbohydrate  metabolism  and  glucose  homeostasis  which  is very much  
essential  for  every  tissue  in  the  body. 
Overview of Blood glucose regulation in fasting and fed   state: 
In Fasting state: 
Both  insulin  and  glucagon, along  epinephrine, nor-epinephrine
(59)
 and  cortisol  
maintains  blood glucose  concentration  in  the  fasting  state  by  upregulation  of  
glycogenolysis,   gluconeogenesis, lipolysis, and  ketogenesis  in   various  stages  and  tissues.  
After  a  meal, glucose level  reaches  a  peak in 1 hour  and  returns  to  fasting  level  
in  2 to 4 hrs. During  first  8 – 12 hrs  of  fasting  the  primary  mechanism  regulating  blood  
glucose  levels  is  liver  glycogenolysis  by  hormone  glucagon  
(60,61)
. Even  in  fasting  state  
a  basal  level  of  insulin  is  secreted  to  control  glucose  disposal  but  this  low  level  of  
insulin  in  the  fasting  state  has  very  negligible  suppression  action  on  glycogenolysis. 
After  12  hrs  of  fasting  ( overnight fasting ) system  enters  a  basal  state  or  postabsorbtive  
state 
(62)
.  
When  most  of  glycogen  were  consumed, gluconeogenesis  begins  to  maintain  
blood  glucose  levels   and  by  24 hrs  of  starvation    when  body  glycogen  stores  gets  
depleted, gluconeogenesis becomes the main  source  of  blood  glucose. In  gluconeogenesis, 
new  non-carbohydrate   precursors   like  lactate  from  muscles  and  RBCs,  glycerol  from  
adipose  tissue  and  major  amino acids (alanine  and  glutamate) from muscles  are  
converted  to  glucose. Low  insulin  level  suppresses  lipogensis  and  activates lipolysis  in  
adipose  tissue  and  release  free  fatty  acids. Muscles  does  not  depend  on   insulin  and   
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prefers  free fatty acids  as  major  fuel  during  rest  and  contraction  sparing  glucose  for  
other  tissues.  
During  prolonged  starvation, a  state  of  stress  and  very  low  level  of  plasma  
insulin results in epinephrine release. Epinephrine  and  Glucagon  activates  phosphorylation   
of  hormone  sensitive  lipase  and  perilipin precipitating  lipolysis 
(63)
. By  3  days  of  
starvation  acetyl coA  gets  accumulated  in  the  liver  and  drives  the  ketone  body  
formation  that  meets  the  energy  need. Thus, a regulated insulin to glucagon ratio is 
essential to maintain blood glucose level in fasting state. 
In  fed  state: 
After  a  meal, there is a postprandial glucose flux, that  maintains  a  balance  between 
glucose appearance  and  glucose  disappearance  or its uptake  in  the  circulation. Glucose  
appearance  is  regulated  by  pancreatic  and  gut  hormones  ( both  hepatic  and  meal  
derived  glucose  production) and  glucose  disappearance  regulated  by   insulin  mediated  
uptake in the peripheral tissue (Pehling et al.),
(64,3)
. Various  glucoregulatory  hormones  are  
insulin  and  amylin  from  beta  cells , glucagon  from  alpha  cells , GLP-1 and GIP  from  
enteroendocrine  cells. 
In  fed  state, plasma  glucose  is  increased  by  ingested  nutrients   that  leads  to   
Insulin   secretion  and  synthesis ,which are  enhanced   by  gut  hormones. Insulin  signals  
insulin  sensitive  peripheral  tissues  for  glucose  uptake  and  promotes  glycogenesis  in  the  
liver. The  secreted  endogenous  insulin  along   with  amylin  from  beta  cells  of  pancreas    
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inhibit   postprandial  Glucagon  secretion  where  Insulin  acts  via  paracrine  action  and  
amylin  via  centrally  mediated  efferent  vagal  signals 
(65)
and  stops   glycogenolysis  and  
gluconeogenesis  in  the  liver. Thus  insulin  acts  to  reduce  blood  glucose  level
(3)
. Insulin  
also has  important  role  in  activation of lipogenesis, storage of triglycerides in adipose 
tissue, protein synthesis in liver  and  muscle  tissues and also cell growth and proliferation
(66)
. 
In T2DM, the  earliest  metabolic  abnormality  detected   was  insulin  resistance  that  
initially  augmented  insulin  secretion  to  offset  the  defect  in  insulin  action  and  maintains  
normal  glucose  tolerance (NGT)
(67)
. However  overtime  when  beta  cells  begins  to  fail, 
leads  to  deterioration  in  glucose  homeostasis  and  ultimately develop T2DM, which  
initially  manifests  with  impaired  glucose  tolerance  and  latter  as  overt  diabetes 
(67)
.The  
emerging  hyperglycemia  with  poor  metabolic  control  leads  to  glycotoxicity  and  further  
declines  insulin  sensitivity
(67)
 progressing  to  other  complications.   
Sufficient  and  regulated  insulin  secretion  is  particularly  needed  to  maintain  
glucose  homeostasis both in fasting and fed state. 
Insulin : 
The  primary  function  of  β-cells  of  pancreas  is  synthesis, storage  and  regulated  
secretion   of  insulin.  Insulin  is  a  major  polypeptide  hormone  secreted  by  pancreas. 
Insulin  is  made  of  A chain  with  21 aminoacids  and  B chain  with  30 amino  acids.  
Insulin  gene  is  located  on  the  chromosome  11p 15.5.
(29) 
.Three  exons  and  two  introns  
are  in  this  gene.  
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Processing  of  insulin  granules : 
The  messenger  RNA  after  splicing  codes  for  the   preproinsulin  peptide
(30)
.  The  
signal  peptide  of  preproinsulin  translocates  it from  cytoplasm  to  lumen  of  rough 
endoplasmic  reticulum  where  the  signal  peptide  is  removed  and  proinsulin  precursor  
molecule  is  generated
(31)
.The  newly  synthesized  proinsulin  gets  accumulated  in  clathrin-
coated  region  of   the  trans- Golgi   network, where  secretory  granules  are  processed
(32)
. 
During the  maturation of secretory  granule, proinsulin   precursor  molecule  is  processed  to  
active  insulin. Thus in the  intracellular  storage  pool  of  β- cells, mature  β granules  made  
of  insulin  in  crystalline  form  along with  soluble  C- peptide are stored. After  receiving  
the  intracellular  signals, insulin  and  C-peptide  are  released  from  secretory  granules   by  
exocytosis
(33). 
Pancreatic  β – cell - insulin granule  pool: 
In  β-  cells  insulin  containing  granules  are  either  free in  cytosol  as  reserve  
granules  or  docked  to  the  plasma   membrane 
(34)
.These  docked   granules   may  be  
primed  or  unprimed. The  primed  granules  may  be in  readily  releasable  group  or 
immediately  releasable  group.
(35) 
Insulin  secretion: 
Insulin  release  primarily  determined  by  blood  glucose  levels. The  number  of  
insulin  granules  released  from  β-cells of the pancreas is also determined by blood glucose  
concentration. Insulin release  is  biphasic. The two phases  in  glucose  stimulated  insulin  
secretion  are: 
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First  phase  of  insulin  secretion: 
As  the  blood  glucose  level  increases,  glucose  is  rapidly  taken  up  and  
metabolized  by  β cells  of  pancreas  via   glucose transporter 2 (SLC2A2/GLUT2).  By  
glucokinase ,glucose  is  converted  to   glucose  6 phosphate  that  completes  glycolysis  and  
enters  Krebs  cycle  resulting  in  increased  cytosolic  ATP  concentration  within  1  min 
(Porterfield  et al. 2000). This  leads  to  closure  of  ATP-sensitive  potassium  channels 
(K
+
ATP)   followed  by  depolarization  of  cell  membrane (Henquin,  1990). Depolarization  
causes  opening  of  voltage  dependant  Ca
+  
channels. As  the  [Ca
2+
]  concentration  
increases  exocytosis  of  insulin  is  triggered.(Fig : 2)  
In the  first  phase  of  insulin  release,   granules  in  the  immediately  releasable  pool  
are  released  first. Number  of  granules  released  depends  upon  glucose  concentration  
followed  by   changes  in  depolarization, Calcium channel  activation  and  increase  in  Ca
2+
 
ion concentration in  the  β- cells 
(36)
.As  Ca  ion  concentration  increases   the  rate  of  
exocytosis   of immediately  releasable  insulin  granules  increases.  Hence  depolarization  of   
ATP – sensitive  potassium  channels  results  in  increased  Ca
2+
  entry and   stimulate  insulin  
release
(37)
.This  is  known as KATP  channel – dependant  signaling  pathway
(38)
.The   
immediately   releasable  granules  makes  up  the  first  phase  of  insulin  secretion  and  the  
size   of  this  pool  is  eminently regulated  by   time  dependant  potentiation  (TDP) and  by  
signaling  molecules  like   Glucogon  like  peptide  -1  and  Pituitary  adenylate  cyclase  -  
activating  polypeptide  (PACAP). (Fig :3) 
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Fig 2 : Glucose Induced Insulin relase 
 
 
 
 
 
 
Fig 3 : First and Second phase of Insulin Release   
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Second  phase  of  insulin  secretion: 
 Once  the  immediately  releasable  granules  has  been  discharged, the size  of   this  
pool  decreases  and   it  is  replenished  by  rapid  transformation  of  readily  releasable  
granules  by  agents  like  Glucogon  like  peptide-1, Pituitary  adenylate  cyclase  -  activating  
polypeptide (PACAP), acetylcholine and cholecystokinin.  As  the  GLP-1  signal  increases, it 
significantly  alters the  size  of  immediately  releasable  granule  pool  by increasing  the size  
followed  by  insulin  exocytosis. This  is known as  KATP channel – independent  signaling  
pathway. 
Thus  the  two  pathways  act  synergistically.  KATP  channel – dependant signaling  
pathway  triggers  insulin  release  by  increasing  Ca
2+
 and   KATP channel – independent  
signaling  pathway  enhances  the  response  to  increased  Ca
2+
.  It is found that  even  in  
absence of extracellular Ca
2+ 
or increase in intracellular  Ca
2+
,KATP channel – independent  
signaling  pathway   can  enhance  insulin  release. 
(39)  
There  exist  a  state  of  equilibrium  between  readily  releasable  and  immediately  
releasable  pool  of primed  docked  granules.  This depends on ambient glucose 
concentration, activity of KATP – channel independent  signaling   pathways   and  effect  of  
time  dependant  potentiation.  Activation of  KATP – channel - independent    pathways and  
TDP  drive  the  equilibrium  bar  towards  the  right thus  it  increases  the  size   of  
immediately  releasable  pool.  Low ambient glucose concentration   as  occuring  during  
fasting  drives  the  equilibrium  bar  towards the  left and  the size of  immediately  releasable  
pool   of the  first  phase  of  insulin  release  is  decreased.(Fig :4) 
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Fig 4 : K
+
 ATP – Dependent & Independent pathways 
 
 
 
 
 
 
Release  of  insulin  from  beta  cells  of  pancreas  mainly  depends  on  blood  glucose  
concentration.  Glucagon  like  peptide -1  (GLP-1)  an  efficient  incretin  hormone  found  to   
potentiate  insulin  synthesis  and  secretion  from  beta  cells  of  pancreas  through  the  
enteroinsulinar  axis  depending  upon  the  blood  glucose  concentration. Hence  significant  
amount  of   potentially  efficient  GLP-1  secretion  is  essential  for  insulin  release  in   the  
postprandial  state .  
In  intestinal  L  cells, the  gene  encoding  GLP-1  is  Proglucagon  gene. The  
Proglucagon  gene  is  not  only  expressed   in  intestinal  cells  but  also  in   pancreatic  cells  
and  brain  cells.  According  to  Darnell in  1982, stated  that  during  gene  expression  a  
diversification  of  genetic  information  can  take  place  at  one  or  more  levels  like  
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1)duplication  and  divergence  of  gene ,  
2) RNA  precursors  undergoing  alternative  splicing  and  
 3) polyproteins  undergoing  alternative  processing 
(48)
.  
For  Proglucagon  gene  tissue  specific  differential  post – translational  processing  of  
proglucagon  polyprotein  determines  different   products   in  various  tissues 
(48) 
. 
Proglucagon  gene  structure: 
In  the  whole  mammalian  species , a  single  unique  gene  encodes  Proglucagon and 
it  is  located   in  chromosome  2q36-37.  Proglucagon  gene  revealed  a  complex structure. 
The  entire  nucleotide  sequence  of  human  proglucagon  gene  spans  nearly  9.4 kilobases   
 
that  includes  6  exons  and  5   introns 
(37)
  into  which  5’flanking  region  along  the  first  
exon  are  also  included.  Exon  include the  sequence  that   code  for  amino acids  of  
specific  protein   and  also  untranslated  sequence  that  are  highly  essential  for  efficient  
translation  of  mRNA  transcript  of  Proglucagon  gene. All  5  introns  matches  the  
consensus  splice  sequences  of  nucleotide   at  5’ end (GT)  and  3’ end (AG).  
Exon 1 encodes 5’ untranslated sequence completely but for 9 nucleotides.  Exon 2  
encodes  part  of  Glicentin  related  pancreatic  peptide (GRPP)  with  the  signal  peptide.  
Exon 3 encodes   remaining part of GRPP along complete Glucagon sequence. Exon 4 
encodes GLP-1 and exon 5 encodes GLP-2. Exon 6  encodes  3’ untranslated  region  along  
last  4  nuleotides  of  coding  region.  After  sequencing  nearly  600  nucleotides   of  
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5’flanking  region,  TATA  box  ( the  core  promoter  sequence  that  forms  preinitiation  
transcription  complex )  was  detected  from  nucleotides  -24  to -19  base   pairs  from  
transcription  start  site  and  not  any  CAAT box  was  found  in  nucleotide  -68 to -65 base  
pairs  representing  complement  of  the consensus  CAAT  sequence.  The  TATA  box  
region  in  the  gene  sequence  was  found  identical  between  species  and  in 5’ flanking  
region of  proximal 130 base  pairs   nearly  88%  of  nucleotide  sequence  are  homologous  
between  species  (rat  and  human)  also  the  CAAT   sequence  from -93 to -50  in  the  44 
nucleotide  stretches  were  identical.  This   shows  the  extreme   importance  of  the  
promoter  region  that  controls  transcription  that  is  being  highly  conserved  through  
evolutions
(49)
.  Introns did  not  show  any  detectable  similarities
(49)
. From  such  a  complex  
Proglucagon  gene, the  mRNA  transcript synthesized  in  pancreas, intestine  and  brain were  
very  much  identical.  
 
Posttranslational processing of  Proglucacon  gene and Products:                 
For  Proglucagon  gene  having  such  a  complex  gene  structure,   its  mRNA  
nucleotide  sequence  was  derived   from  human cDNA( Bell et al. 1983b)  and  from  that   
the  structure  of  precursor  proglucagon  was  deduced. More  than  90% of  amino  acid  
sequence  were  found  homologous  to  other  mammalian  species 
(49)
. The  precursor  
Proglucagon   having   large  molecular  weight   was  found  to  made  of  160  aminoacids. 
The precursor Progluacgon   undergoes    endoproteolytic  cleavage  in  the  process  of   post-
translational  modifications. The  various  proglucagon  derived  peptides  (PGDPs)  were  
Glucagon, Glicentin, Glicentin – related  pancreatic  polypeptide (GRPP), Oxyntomodulin, 
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Major  Proglucagon  Fragment (MPGF)  including  Glucagon – like  peptide 1 and  Glucagon 
like peptide 2  (Mojsov et al.,1986). Such  a  diversified  expression  of   Proglucagon  gene  
product  is  mainly  by  differential  tissue  specific  post translational  processing. This  
differential  processing  of   proglucagon  gene  takes  place in   α cells  of  endocrine  
pancreas,  enteroendocrine  L  of  intestine  and  brain   neuronal ( hypothalamus  and  nucleus  
of  solitary  tract)  cells. Each   Proglucagon  gene  products  exhibits  specific  functions that  
regulates  blood  glucose  homeostasis,  cell  proliferation  and  satiety  significantly.
(47)
 
(Fig:5) 
 
Fig 5: Expression of Proglucagon Gene and its Products 
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Processing in  pancreatic  α cells: 
 
In  the  α cells  of  pancreas   Prohormone  convertase  2( PC2)  is  coexpressed   
during the  processing  of   proglucagon   gene. By  proteolytic  cleavage  by  PC2, precursor   
 
 
Proglucagon yields four fragments. The  main  products  are  Glucagon, Major  Proglucagon  
Fragment, Glicentin  related  pancreatic  peptide  and  an  Intervening  peptide.  
 
1. Glucagon:  
Glucagon  is  made  of   29  aminoacids  that  corresponds  to   33 to 61 amino acid 
position    starting  at  the  N terminal  amino  acid  within the  proglucagon peptide ( PG 33-
61). The  glucagon  sequence  in  proglucagon  gene  is  flanked  by  pairs  of  basic  amino  
acids  that  acts  as  cleavage  site  for  specific  bioactive  peptide  release. (Steiner et al., 
1980)
(48)
.  
 
Glucagon  is  an  important  peptide  hormone  from  α cells  of  pancreas. Glucagon  
has  a  major  role  in  glucose  homeostasis   by  opposing   the  action  of  insulin  and 
activating   hepatic  glycogenolysis  and  gluconeogenesis (Lefebvre, 1983; Unger and Orci, 
1981; Habener, et al., 1985). Glucagon  is  secreted  when  blood  glucose  level  is  low. But  
repeated  episodes  of  hypoglycemia  leads  to  impairment  in  counter  regulation  by 
deficient  or  absent  glucagon  secretion  in  response  to  hypoglycemia 
(50)
. 
 
It  is  well  known  that  in  pancreatic  α  cells  insulin  inhibits  proglucagon  gene  
expression  as  glucagon  is  the  primary  counterregulatory  hormone  of  insulin  and  it  is  a  
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physiological  inhibitory  response.  In T2DM,  either  due  to  insulin  resistance  in  α cells  
or  low  insulin  level  leads  to  dysinhibition  of  glucagon  secretion  after  a  meal
(51)
.  
                    
2. Major Proglucagon  Fragment : 
 MPF is  a  large  unprocessed  polypeptide  of  molecular weight approximately 10,000  
that  was secreted  in  parallel  with  glucagon
(52)
.It  corresponds  to  PG 72-158. 
 
3. A  Glicentin  Related  Pancreatic  Peptide   
 
GRPP  corresponding  to  PG  1-33  and  an  intervening  peptide1, a  small  fragment  
of  proglucagon  sequence  corresponding  to  PG  64-69  were  also  secreted
(50)
. 
 
For  Proglucagon  gene  expression  in  α cells  of  pancreas, transcription  factors  play  
a  significant  role   that   acts  on  the  promoter  sequence  and  initiates  transcription  of 
proglucagon  gene. Insulin  was  found  to  directly  inhibit  proglucagon  gene  expression  by  
regulating  gene  transcription
(53)
. Insulin regulates   transcription via  insulin  responsive  - 
DNA  elements
(68)
.  Insulin  action  were  confirmed  by  interaction  of  Transcription  factor  
Pax6   with  proximal  promoter  and  more  distal  enhancer - like  element
(69)
.  Other  
transcription  factors  that  regulate  proglucagon  gene  expression  are  Fox 01, isl-1,cdx-
2/3, pax-6, HNF-3a, HNF-3b, and brn 4 
(70,71)
. 
 
Processing  in  Brain  Cells:                    
     
In  Central  nervous  system, Proglucagon  gene  are  expressed  in  nucleus  of  
solitary  tract  of  brain  stem  that  projects  fibres  to  hypothalamus, arcuate  nuclei  and  
paraventricular  nuclei. Processing  of  Proglucagon  gene  showed  pronounced  contribution  
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to  Oxyntomodulin   along  GLP-1 and  GLP-2 . Effect  of  GLP-1  in  CNS  is  regulation  of  
appetite  (Turton et al., 1996; Gutzwiller et al.,1999; Verdich et al., 2001)  and  delaying  
gastric  emptying (Schirra et al., 1997). It  is  found  to  regulate  food  intake  and  maintain  
nutrient  homeostasis 
(48,72,73)
.                                          
 
Processing in Intestinal L cells: 
In the intestine, L cells are  distributed  more  in the  distal  ilieum. During  
proglucagon  processing   Prohormone  convertase 1  is  coexpressed   in  L cells, that   yields  
Glicentin, Oxyntomodulin, two Glucagon like peptides (GLP-1 and GLP-2) and an 
intervening  peptides  2 ( IP-2) 
(38) 
 by  Prohormone  Convertase 1(PC1)
(74)
. 
1. Glicentin : 
The amino terminal part of  proglucagon  gene  yields  Glicentin. It is made of 69 
amino acids. It corresponding to PG 1-69. Exogenous  Glicentin   were  administered and  it  
showed stimulatory  effect on  small  bowel  growth  in  rodents 
(75)
. Specific receptor for 
Glicentin are not  found . 
2. Oxyntomodulin :       
 
Glicentin  peptide  may  either  remain  uncleaved  or  get  partly  cleaved   to  form  
Oxyntomodulin. It is made of 37 amino  acids. It corresponds to PG 33-69.  Oxyntomodulin  
has  anorectic  action  by  stimulating  satiety  and  gastric  acid  secretion. It is used in 
antiobesity drugs (Murphy et al. 2006).  It exerts its action through GLP-1R signaling 
system
(76)
.  
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3. Glucagon  like  peptides : 
 
The  Major  Proglucagon  Fragment  containing  GLP-1  and  GLP-2  peptides.  It  has  
a canonical  cleavage  sites  made  of  pairs  of  basic  amino acids  flanking  both  the GLP  
sequences  for  the  action  of  prohormone  convertases 1 (PC 1).  Proteolytic   cleavage at 
this site  yields   GLP-1 (PG 72-108)   and  GLP-2 ( PG 126-158)
(53)
. (Fig:6) 
 
Fig:6 Proglucagon Gene Products in Pancreas, Gut and Bra 
in 
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GLP-1  peptite  structure:                        
GLP- is a  peptide  hormone. It exists in 4 isopeptides   forms – GLP-1(1-37), GLP-1 
(1-36),  GLP-1 (7-37), GLP-1 ( 7-36).  GLP-1(1-37)   and  GLP(1-36) amide  have  37  and  
36  amino  acids  respectively   corresponding  to  PG 72-108. The   two  amino  terminally  
truncated  isopeptides  GLP-1(7-37)  and  GLP-1(7-36) amide  have  31  and  30  amino  acids  
respectively   corresponding  to  PG 78 – 108 
(54)
.   
The   Amino terminally truncated  forms  of  GLP-1  has  distinct  insulinotropic  
activity. GLP-1(1-37) may  be  called  as  prohormone  having  arginine  in  6
th
 and  histidine  
in  7
th
  position  that  by  cleavage  at  single  arginine  residue  at  6
th
  position  yields  GLP-1 
(7-37) the  active  form (Lund et al., 1983)
(47)
. In  this  amino  terminally  truncated  form  the  
108
th
   amino  acid  corresponding  to  glycine  can  get  amidated  with  the  carboxy  terminal  
of  Arginine  residue.  
Truncated  GLP-1  exist  in  two  equipotent  forms  as  amidated  GLP-1(7-36)  or  
Glycine  extended (7-37)   form.  In  human gut  most  of  the  GLP-1  are  secreted  in  
amidated  form  GLP-1(7-36)  having   30 amino acids. Amidated  GLP-1    are     more  
active  form  and  shows  slightly  more  resistance  to  plasma  enzymes  DPP-4
(77)
. GLP-1  in  
full length  is  inactive. 
Stimulus  for  GLP-1  secretion  in  L cells: 
Morphologically  intestinal  L  cells  and  pancreatic  α  cells  differ  in the  shape  of  
granules  where  α  cells  have  core  of  dense  material  surrounded  by  less  dense  halo  and   
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L cell  granules  are  homogenous  without  any  halo
(78)
. The  enteroendocrine  L  cells, 
known  as  open  type  endocrine  cell  have  slender  triangular  base  seated  on  the  basal  
lamina  with  elongated  cytoplasmic  process  with  microvilli  that  open  into  gut  lumen. 
Nutrients  may  be  sensed  by  these  microvilli  and  transmit  the  message  for  secretion  of  
hormones
(78)
. Neural  and  hormonal  signals  from  proximal  gut  were  also  found  to  be  
efficient  indirect  signals  for  GLP-1  secretion 
(50)
.  But  when  insulin  is  present  in  
pathological  concentration  like   hyperinsulinemic  status  and  insulin -  resistant  status    it  
shows  a  strong  stimulatory  effect  on  proglucagon  mRNA   expression  and  GLP-1  
production   in  intestinal  L  cells  Yi et al.,
(79)
  eluding  the  fact  that   there  exist  a  crosstalk  
between   Wnt  signaling  pathway  and   insulin  affecting  the  homeostasis  of  GLP-1 
(79)
. 
 
Metabolism of GLP-1: 
Intact GLP-1 has a very short  half -life  of  1-2  minutes  in  circulation. It  is  rapidly  
degraded   by enzyme  Dipeptidyl  peptidase 4  (DPP 4)  and  neutral  endopeptidases. DPP4  
is  expressed  on  brush  border  of  enterocytes  and   lamina  propria  of  endothelial  cells   
lining  the  capillaries
(50)
. The  catalytic  action  of   DPP4  cleaves  off  the  two  amino  
terminal  amino  acids  of  GLP-1 ( cleaves at His7 and alanine 8)  generating   inactive  GLP-
1 (9-36)  and  GLP-1 ( 9-37) amides  named  as  GLP-1m. Metabolic  clearance  rate  of   
inactive  GLP-1  by  kidney  is  very  rapid  with  a  half  life  of  4-5 mins 
(80,81)
. 
Stimulus for GLP-1 secretion:  
 
Major  amount  of  GLP-1  secretion  is  strictly  meal  dependant
(82)
 even  though  a  
basal  rate  of  secretion  is  maintained.  GLP-1  secretion  depends  on  the  size  of  the  meal  
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and  in  accordance  to  gastric  emptying  rate 
(83,84)
.  Along  carbohydrates  lipids  also  
provide  strong  stimulus  for  GLP-1  secretion  in L cells 
(85)
. 
         
Actions  of  GLP-1 : (fig:7) 
1. GLP-1   has  main  effect  on  insulin  synthesis  and  secretion  in  β cells  of  
pancreas.  
 
2. Effect  on   α cells  of  pancreas:  
GLP-1 also has effect on α cells of pancreas. Glucagon secretion is strongly inhibited 
by GLP-1
(54)
.  It  exerts  its  inhibitory  effect  when  glucose  level  is  at  or  above  
fasting  level. The inhibitory   mechanism of GLP-1 on glucagon   is not completely 
elucidate. Suppresion  of  glucogon  release   may  be  either  directly  by  GLP-1 
action  or  indirectly  as  paracrine  action  of  insulin  itself 
(42) (44) (45)
.        
3. Effect  on  δ cells  of  pancreas : 
GLP-1     stimulates  δ   cells  of  pancreas  and  stimulate    somatostatin  release  
which  produces  a  short  loop  negative  feedback  on  insulin  secretion.   
 
The extrapancreatic actions  of  GLP-1 are  
4. Effects  on  Gastrointestinal Tract : 
GLP-1 is known as  a  enterogastrone. It  exhibits  strong  inhibitory  action  on    
gastrointestinal  secretion  and  motility  by  inhibiting  gastric  emptying 
(86,54)
.  It has 
effect  as  ‘ileal  brake.  It  exerts “ Ileal  break  effect”  via  afferent  sensory  neurons  
by  regulating  parasympathetic  neurons
(54)
.  
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5. Effect  in   heart: 
GLP-1 shows cardio-protective and  cardiotropic  effects  on  heart. The  
inactive  amide  form    GLP-1m  exhibits  protective  effect   on  heart.(Choand 
Kieffer,2011)
(87)
. 
 
6. Effect  in  Liver: 
The  GLP-1 (28-36)  a  short  peptide  showed  some  beneficial  metabolic  
effect  in  liver  and  pancreas  by the study Liu et al.,.
(87)
It  regulates  hepatic  glucose  
production by  D'Alessio et al.,.
(88)
 
 
7. GLP-1m , the  degradation  product  of  GLP-1  said  to  have  insulinomimetic  effects  
on  cardiac  function  and  hepatic  glucose  production.
(89)
 
 
8. GLP-1  has  effect  on  exocrine  pancreas  by  inhibiting  the  secretion. 
 
9. Effect in Brain:       GLP-1   regulates  satiety    through  GLP-1  receptors  in  brain 
.Its  effect  on  appetite  and  food  intake  found  to  contributes  to  obesity  partly.
(89)
  
 
10. Physiological  action  of  GLP-1  is  found  to  increase  peripheral  insulin  
sensitivity
(91)
.  
 
11.  During  circulation  in  capillaries, interact  with  afferent  nerve  fibres  emerging  
from    nodosa  ganglion   and  transmit  signals  to  solitary  tract  and  
hypothalamus
(54)
. 
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Fig:7 Functions of Glucagon like Peptide -1 (GLP-1) 
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Glucose  homeostasis – regulation by GLP-1: 
              
GLP-1 exerts its action through specific GLP-1 receptors. Human  GLP-1 receptor  
gene  spans  40  kb  with  nearly  7  exons  is  located  in  chromosome  6 ( chr 6p21). GLP-1 
receptor  are  made  of  463  amino acids. It  is  a  seven  membrane  spanning,  class 2,  
heterotrimeric, G – protein  coupled  Receptor
(95)
. GLP-1  receptors  are  chiefly  found  in  
endocrine  pancreas  but  also  located  in  multiple  tissues  and  cell  type  like  central (brain 
stem, thalamus, hypothalamus) and  peripheral  nervous  system, stomach ,duodenum ,heart, 
lungs, gastrointestinal  tract, liver and  kidney
(91)
.    
 
Mechanism of GLP-1 on β-cells of pancreas:              
In  β cells  of  pancreas, GLP-1  is  an  efficient  direct  stimulator  of  insulin  release  
mediated  by  cAMP. In pancreas , GLP-1 also  activates  signal  to  proinsulin  gene  
transcription  through  the  transcription  factor  PDX-1
(54)
, for  biosynthesis  of  insulin 
(91, 49)
, 
stimulates  signal – transduction  pathways  involved  in  proliferative  and  cytoprotective  
actions  for  maintaining  mitogenesis  and  cell  survival of β-cells .
(50). 
 
 
Action of GLP-1 on β cells  of  pancreas  depends  directly  on  the  blood  glucose  
concentration
(50)
. There  exists  a  synergistic  cross  talk  between  glycolysis, on entry of 
glucose  and  cAMP, activated  by  GLP-1  signalling  pathway. Thus  β-cells  require  
glucose, to  respond  to  GLP-1  and   GLP-1, to remain  competent  to  respond  to  rising   
glucose  levels. This  mutual  regulation  between  GLP-1  action  and  glucose  metabolism  is  
said  as  Glucose  Competence  Concept
(43)
 . (Fig:8) 
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Fig:8 Glucose  Competence  Concept: 
 
 
 
 
 
 
 
 
 
 
Fig: 9 Mechanism of GLP-1 induced Insulin Release 
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Cellular  signaling  through   GLP-1  receptor  is  mediated  by  Gα  and  cAMP  pathway
(48)
. 
GLP-1  binds  to  its  G  protein  coupled  receptor  and  activates   adenyl   cyclase  that  
catalyses  the  conversion  of  ATP  to  cAMP, which   acts  as  second  messenger  that  
allosterically   activates  PKA  and  cAMP –GEFII  also  called  as  Epac2  factor  and  
enhances   Ca
2+
 dependant   insulin  exocytosis  (CIE)
(91)
. cAMP-GEF/Epac 2  factor  activates 
rapid  exocytosis  of  insulin  granules  and  cAMP- PKA  dependent  pathway  by  prolonged  
depolarization  shows  slow  exocytosis
(94)
. (Fig:9) 
 
GLP-1 activates   cAMP – PKA signals and blocks K-ATP channel, potentiating 
insulin release.  These  signals  also  increase   L type  VDCCs  activity  that  enhances  Ca  
influx  leading  to  insulin  release. Thus, cAMP –PKA dependant  signals  potentiates  insulin  
granule  mobilization
(93)
 and  enhances  first  phase  of  insulin  secretion .  
 
Epac2  factor   is  found  to  be  involved  in  both  phases  of  insulin  secretion. GLP-1   
activates  cAMP   mediated   cAMP-GEF/Epac 2  factor  regulates  PKA - independent  
mechanism  of  insulin  release
(94)
. For  cAMP—regulated  insulin  granule  exocytosis, a  
coordinated  interaction  of  cAMP-GEF/Epac 2, Rim2, Piccolo  and  Rab3  takes place
(94)
. 
This  coordinated  complex  is  formed  by  specific  interaction  of  cAMP-GEF/Epac 2   with  
nucleotide- binding   fold   (NBF)-1   of   the   SUR1   subunit   of   KATP  channels.  Insulin  
granule  with  putative  SUR   found  to  coupled  with  Cl
-
 channel (ClC3). As  cAMP-
GEF/Epac 2  binds  to  such  SUR  subunit, ClC3  channels  are  opened  allows  entry  of  Cl- 
ions  into  the  insulin  granules. Thus  acidification  of  granules  leads  to  priming  of  
secretory  granules  and   replenish  the  readily  releasable  pool
(94)
.  GLP-1  activates  
Ryanodin  receptor (RYRs) (Holz et al., 1999),  on  endoplasmic  reticulum  membrane  of  
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pancreatic  β cells  through   cAMP-GEFII/Epac2   for  Calcium  mobilization  and  
potentiates  insulin  exocytosis 
(94)
. 
 
Thus  ATP  sensitive  K channels  are  closed  by  the  synergitic  action  of  GLP-1 
and  glucose. Induction  of  electrical  activity   due  to  depolarization  leads  to  influx  of  
Ca
2+ 
 ions.   As  the  glucose  and  GLP-1  level  increases, through   PKA  and   cAMP-
GEFII/Epac2  -dependent   mechanisms  Ca2
+  
channels  feeds  forward  into  mobilization  of  
intracellular  stores  of  Ca
2+
. Increased  Ca  enhances  mitochondrial  ATP  synthesis  and  
triggers  insulin  exocytosis  that  is  continuously  potentiated  by  cAMP.   
 
Thus,  cAMP  was found to potentiate  both  first  and  second  phase  of  Glucose  
induced  insulin  secretion  where  Ca
2+
 and  cAMP    interact  cordially  with  each other.  As  
glucose  increases  Ca  entry,  the  Ca
2+
/CaM   complex  activates  Type  VIII  adenyl  cyclase  
leading  to  increased  cAMP  level
(92)
 which   potentiates  insulin  release  by  both  PKA  
dependant  and  PKA  independent  mechanism 
(94)
. Quantitatively  the  ability  of  cAMP  to  
increase  the  size  of  immediately  releasable  pool  by  accelerating  granule  mobilization   
is  the  most  important   one  contributing  more  than  70%  of  total  insulinotropic  activity  
of  GLP-1.
(54)
 
 
Hence, GLP-1 found  to  have  glucoregulatory,  proliferative  and  cytoprotective  
action  on β-cells of panceas. 
 
GLP-1  in  Type 2 Diabetes : 
 
In  recent  research   about  development  and  treatment  of  T2DM, the  main  clinical  
interest   is  focused  in  GLP-1.  Many  studies  postulated  that  T2DM may  be  due  to  
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reduced  or  absent  incretin  effect
(54)
. With  respect  to  GIP,   secretion  is   normal  or  near  
normal  but  defect  is  mainly  due  to  complete  loss  of insulinotropic  effect
(54)
.  But  with  
GLP-1,  its  insulinotropic  effect  is  completely  preserved  but  a  significant  or  sometimes  
substantial   reduction  in  GLP-1  secretion  is  seen  leading  to  T2DM
(54)
.   
 
Intestinal  L  cells  secrete  GLP-1  acts  as  a potent  stimulator  on  beta cells of  
pancreas. It significantly increase insulin release along with insulin synthesis. GLP-1 also 
activates satiety center in brain regulating obesity. The pathway of GLP-1 synthesis, secretion 
and its action in various tissues is complex. Hence, defect in its pathway leads to various 
disorders of which its association with type 2 DM is more clinically specific.         
 
In  the  mechanism of  Proglucagon  gene  expression  for  the  synthesis  of  GLP-1, 
many  transcriptional  factors  have  essential  role. Of  which  transcription  factor  TCF7L2  
was  found  to be  one  of  the  main  initiator  of  promoter  region  of  proglucagon  gene 
through  Wnt  pathway leading to GLP-1 production. Many  studies  proved   that  TCF7L2  
gene  polymorphism which  is found to alter this pathway, is  associated  with Type 2 Diabetes  
Mellitus, done in  various  populations. 
 
Transcription  factors  affecting  Proglucagon  gene  expression in Intestinal 
L cells:  
 
Gene  expression  can  be  modulated  in  any  step,  from  DNA-RNA transcription  
step  till  post  translational  modification  of  the  proteins. The  ProGlucagon  gene  encodes  
a  large  biosynthetic  precursor and its expression  in  intestinal  L  cells  is  regulated  at  
many  levels   and  final  products  are  GLP-1, GLP-2, Glicentin  and  Oxyntomodulin. 
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Proglucagon  gene   expression  regulated  at  various  levels are: 
 
1.  During  transcription  by  transcription  factors  that  shows   tissue  specificity 
on promoter  region, 
2. During RNA processing  by  alternative  splicing, 
3. By  tissue  specific  post-translational  processing. 
                
Transcription  of  a  gene  in  a  DNA  is  initiated  at  the  promoter  region.  During  
the  exploration  of  Proglucagon  gene  in  rodents  and  humans, a minimum  G1  promotor  
region  and  four  G2-G5  enhancer  elements  were  identified  in  its  promoter  region.  
Various  regulating  factors  of   Proglucagon  gene  transcription  were   identified, they  are   
cAMP, amino  acids ,insulin  hormone, Wnt  signally  pathway  and  many  CAT/TCF  like  
homeodomain (HD)  protein  transcription  factors
(97)
.  
Isl-1, a transcription factor is  found  to  regulate  transcription  of  insulin  gene, 
proglucagon  gene and  somatostatin  gene in  islet  cells  of  pancreas  that  secrete  various  
hormones 
(97)
. 
 
Pax – 2  proteins  were  found  to  promote  gcg  transcription  by  binding  to  motifs  
between  G3  and  G1  enhancer  elements  in  intestinal  endocrine  L  cell,  following  an  
adenovirus  -  mediated  overexpression  method .
(97) 
 
Cdx-2,  a  caudal- like  HD  protein  expressed  in  pancreatic  and  intestinal  gcg-
producing  endocrine  cells
(97)
.   
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cAMP  in proglucagon  transcripiton in Intestinal L cells: 
                         
 
Proglucagon   gene  expression  is  activated  by  cAMP  signals  through  CRE  and  
other  cAMP  response  elements. In both pancreatic α cells  and  intestinal  L  cells  a  typical  
cAMP  response  element (CRE) region at  -291  and  -298 bp  within  the  proximal  gcg  
promoter  region, is  recognized  by  cAMP  signals, for Proglucagon  gene  expression .
(97)
  A  
significant  increase  in  mRNA  expression  and  GLP-1  production  is  processed  by  either  
cAMP  promoting  agents  or  membrane  permeable  cAMP  analogs (Drucker et al.1994) by  
activating  this  motif.  But  by  deleting  or  mutating  this  CRE  motif, only  a  partial  
repression  was  found  on  its  stimulatory  effect  on  gcg  promoter  expression
(97)
. 
 
The  second  messenger  for  cAMP  is  not  only  PKA  but  was  also  found  to   be  
by  Epac-1  and  Epac-2 also called as cAMP-GEFs). Epac  molecules  mediate  its  effect  of  
cAMP  by  activating  Rap-1-Raf-MEK-ERK  signaling  pathway. Expression  of  Epac -2  on  
intestinal  endocrine  L  cells  has  been  reported and found to be  involved  in  the  regulation  
of  HD protein  Cdx-2  through  MEK-ERK  signaling  cascade  for  the  gcg  gene  
transcription  and  expression. (Chen et al. 2005)
(97)
. 
For   the  Proglucagon  gene  expression in  the  intestinal  endocrine  cells,  the  chief  
pathway  is  the  Canonical  Wnt  signaling  pathway  and  the  key  effector  is  the  bipartite  
transcription  factor β – Catenin/TCF7L2(Yi et al. 2005). Wnt gene  along  their  receptors  are  
expressed  in  pancreatic  islet  cells  (Heller et al. 2003) and intestinal  L  cells epithelia 
(97)
.   
Wnt  signaling  pathway: 
 
 Wnt  signaling  pathway  was  first  identified  during  the research  in  breast  cancer  
and  the  embryological  studies  in  Drosophila,  Xenopus. Wnt proteins are secreted as  lipid   
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-modified  signaling  glycoproteins. In  Wnt  signaling  these  proteins  act  as  ligands  to  
activate  many  different  Wnt  pathways. Among  Homosapiens  nearly  19  Wnt  ligands  
have  been  identified. They  are Wnt1,  Wnt2,  Wnt2B,  Wnt3,   Wnt3A,  Wnt4,  Wnt5A, 
Wnt5B,  Wnt6,  Wnt7A, Wnt7B,  Wnt8A,  Wnt8B,  Wnt9A,  Wnt9B, Wnt10A, 
Wnt10B, Wnt11, Wnt16. The Wnt  ligand  found  in  intestine  is  Wnt-9b/14b/15 ( Bouillet, 
P. et al.,). In  Wnt – 9b  357 amino  acid  precursor  with  the  signal  sequence  constituting  
22 aa  and  a  mature  segment  of  335  aa.  There  are  24  cysteines  in  mature  segment that  
under  goes  palmitoylation  and  initiates  targeting  of   Wnt  ligands  to  specific  receptors.   
The two categories of Wnt pathway are canonical  and  noncanonical . The three established 
Wnt signaling pathways are    
 
1. Canonical pathway in which protein   β- catenin is involved,   
2. Non-canonical planar cell polarity pathway and  
3.  Non-canonical Wnt/Calcium pathway.  
Non – canonical pathways operates independent of β-catenin
(98)
. 
The  Canonical β- catenin  signal pathway  or  Wnt/β-catenin  pathway:  
Wnt  receptor : 
 
Wnt  lipoglycoproteins  binds  to  receptors  of  Frizzled  family  (Fz) and  many  
coreceptors  like  lipoprotein  receptor-related  protein  (LRP) – 5/6, Receptor  tyrosine  kinase 
(Ryk), ROR2. In  humans  19  Wnt  family  proteins  and  10  Frizzled  receptors  were  
identified. All members  in  Frizzled  family  receptor  are  similar.  Frizzled  receptor  is  a  G 
protein coupled  receptor  has   divergent  N-terminal  signal  peptide, highly  conserved  
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extracellular  cysteine rich domain (CRD), seven  transmembrane  spanning  domain, variable  
length  linker  region  and  variable  C terminal  region.  Proglucagon gene transcription is 
mediated by Wnt/β-catenin  pathway. In  its  pathway  Wnt  ligand  binds  to  CRD  region  of  
Frizzled receptor with coreceptor as LRP-5/6. Thus, Wnt/Frizzled signal cascade is 
activated
(99)
.  
Fig:10 The Canonical β- catenin  signal pathway  or 
Wnt/β-catenin  pathway: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The  activated  Frizzled  receptor  sends  Wnt signals  to  the   phosphoprotein  
Dishevelled (Dsh/Dvl)  present  in  the   cytoplasm  by  phosphorylation  or  kinases . Dsh  
protein  has  a  highly  conserved  protein  domains- an DIX amino  terminal  domain  (Dsh  
and  Axin), a PDZ  central  domain ( Postsynaptic density-95,Discs-large, Zonula occludens-
1) and  a DEP carboxy  terminal  domain ( Dsh ,Egl-10 ,Pleckstrin). These  different  domains  
of  Dsh  protein  are  significant  determining  factor  in  tranducing   Wnt  signals  into  three  
separate  branches– the Canonical, non-canonical and  Ca
2+  
pathways. In  Canonical  
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pathway,  Wnt  signaling   uses  DIX  and  PDZ  domains  of  Dsh  to  stabilize  cytosolic  β  
catenin
(100)
. 
                   
In  the  absence  of  Wnt  signal,   the  transcriptional  coactivator  β-catenin  is  not  
allowed  to  accumulate   and  is  degraded  by  a  multiprotein  “destruction  complex”. The  
complex  of  proteins  in  destruction  complex  are  tumor  suppressors  Axin   and  
adenomatous  polypoisis  coli (APC), the  Ser / Thr  Glycogen  synthase  Kinases (GSK-3β), 
GSK3- binding  protein (GBP), Casein  Kinases 1 (CK1),Protein  phosphatase 2A (PP2A) and  
the  E3- ubiquitin  ligase  ( β-TrCP / β-transducin  repeat  containing  protein)
(100)
.  In  the  
destruction  complex,  phosphorylation  of  CK1  at  ser45  followed  by  phosphorylation  of  
Ser33, Ser37  and  Thr41 by  Glycogen  synthase  Kinase (GSK3). This  phosphorylation   
 
generates  a  β- TrCP  recognition  site  near  the  β catenin  amino  terminus, which  requires  
scaffolding  of  the  β catenin  and  kinases  by  Axin. Hence, β –TrCP  mediated  
ubiquitinated  β – Catenin  is  subsequently  degraded  by  the  proteasome(99). 
 
In  the  presence  of  Wnt  signal, there  is  immediate  recruitment  of  Axin  protein  
complex  to  the  activated  Wnt  receptor  followed  by  GSK-3 beta  and  CK 1  
phosphorylating  LRP-5/6  coreceptor. The  Axin-1  complex  translocation  disrupts  the  
process  of  beta- catenin  phosphorylation  and  degradation. Thus  the binding  of  Wnt  
ligands  to  the  cysteine – rich  domain  of  Frizzled  receptors  resulted  in  disassembly  of  
the  destruction  complex  containing  axin, APC and  GSK3  leading   to  stabilization  of  β 
catenin.  Beta  catenin  gets  accumulated  and   is  eventually  imported  into  the  nucleus 
where  it   serves  as  transcription  activator  of  the  TCF/LEF-1  family  of  DNA  binding  
proteins
(99)
. 
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Wnt  signals  have  a  wide  range  of  fundamental  cellular  processes  such  as  stem  
cell  maintenance,  embryonic  development, cell  fate,  cell proliferation,  cell migration, 
tumour  suppression and  oncogenesis
(101)
.  
                                             
In  Wnt  signaling   pathway ,the  TCF  factor   binding  motif  is  located   within  the  
G2  enhancer  element  in  the  gcg  promoter  region. This  region  was  already  demonstrated   
that  was  found  to  mediate   the  effect   of   cAMP  and  Calcium  on   gcg  promoter  
expression. Then   it  was   proposed  that   there  could  be  a  crosstalk  between  Wnt  
signaling   pathway  and  the  cAMP – PKA signaling   in   the  intestinal  endocrine  L  cells  
(Yi et al. 2005).  More  recently  evidences   support   the  existence  of  crosstalk  between  
insulin  and  Wnt  signaling  pathway, when  a  pathological  dose  of  insulin  given, it   
utilised   the  same  elements  in  the  gcg  promoter  region  and  stimulated  gcg mRNA  
expression  and  GLP-1  production  (Yi et al. 2008 ). (Fig:10) 
 
TCF7L2 is an important transcription factor that regulates GLP-1 production. Before 
going in to the effects of TCF7L2 polymorphism, a short review about TCF/LEF family.  
                                                                 
TCF/LEF  family: 
 
T–cell  factor   (Tcf-1)  and  Lymphoid  enhancing  factor-1 (Lef-1)  are  the  founding  
members  of  the  TCF  family. 
(28)
 TCF/LEF  family  is  a  group  of  transcription  factors  
that  is  involved  in  Wnt  signaling  pathway  by  binding  to  DNA  through  high  mobility  
group  box (HMG  box). These  transcription  factors   mediate  Wnt  signal  pathway   by  
recruiting  co-activator  beta  catenin  that  enhances  the  elements  of  the  gene  or  by  
recruiting  co-repressors  Groucho  family  members  that  represses   the  target   gene   
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transcription.  In  a specific  cell type if  Wnt  signal  is  absent, the  promoter  DNA  shows  a  
high  level  of  DNA  methylation  and  also  repressive  trimethylation  of  lysine  27  in  
histone  H3 ( H3K27me3). Hence if  Wnt  signals  are  absent, Wnt/β-catenin  target  genes  
become  non-responsive  and  shows  absence  of  active  histone  modification  and  Tcf/Lef  
proteins
(102)
. The  apparent  inability  to  cope  with  chromatin  uncovers  an  intrinsic  
property  of  TCF/LEF  proteins  that  prevents  false  ectopic  induction  and  ensures  
spatiotemporal  stability  of  Wnt/β – catenin  target expression 
(102)
. 
Human members  of  TCF/LEF  family and Genes  encoding are 
1. TCF7 (TCF-1) -       Tcf7 
2. TCF7L1 (TCF-3)     -       Tcf7l1 
3. TCF7L2 (TCF-4)    -        Tcf7l2  
4.  LEF.                       -        Lef1. 
Tcf/Lef  genes  show  high  tissue – specific  expression  patterns
(102)
.For  certain  
developmental  processes  individual  Tcf/Lef  genes shows  unique  requirement  which  if  
absent  leads  to  loss  of  function 
(102)
. The  structure  of  Tcf/Lef  protein  family  shows  N-
terminal  β-catenin  binding  domain, sites  for -related-gene (Grg)/transducin-like enhancer of 
split (TLE) transcriptional co-repressors,  a  high  mobility group box (HMG-box ) DNA  
binding  domain  and  an  adjacent  nuclear  localization  signals
(102)
. Even  though  Tcf/Lef  
protein  family  show  similar  structure  they  are  Promotor  specific  non-redundant  proteins  
whose  function  differs  with  their  domain  composition
(102)
.  Such  a  structural  divergence  
is   further  enhanced  by extensive  and  tissue  specific   alternative  splicing  in  particular  
during  the  synthesis  of  Tcf7 and  Tcf7l2  proteins
(102)
.  
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Tcf-1  is  exclusively  expressed  in  T  lymphocytes  and  Lef  is  expressed  in  both T 
cells  and  early  B  cells  [T1]  shows  Tcf-1  and  Lef  are  essential  for  early  T-cell  
development. They  adopt  a  distinct  genetic  wring  that  activates  the  CD4
+ 
T  cell  fate  
and  an  identity  to  CD8
+ 
T  cells. The  effect  of  Tcf/Lef  transcription  factor   in CD4  
verses  CD8  lineage  choice  is  mediated  by  activation  of  transcription  factor  Th-POK. In  
cell  type  specific  induction  study   when  Tcf1 , Tcf3 along Tcf1E splice  variant   and  Tcf4  
expression  were  changed, it  lead  to  loss/change  in  induction  of  T/Bra , Cdx1,Cdx2 and  
Sp5Wnt  target  genes  showing  that  these  transcription  factors  mediate  Wnt  induction  of  
its  target  gene 
(102)
.  In  a  study  β-catenin/Tcf-4  axis  showed  profound  effects  on  
astrocyte  biology.  It  was  found  that  β-catenin /Tcf-4  axis  influence  the  basal  level  of  
HIV  transcription  in  astrocytes  contributing  to  the  progressing  neuroinflammation
(103)
.   
 
The  Wnt  signaling  associated  transcription  factor  TCF7L2  is  expressed  in  many  
tissues  including  gut  and  pancreas. Many  studies  proved  the  effective β-catenin/TCF7L2   
axis  in  initiating  transcription  at  the  proglucagon    promoter  region  and   GLP-1  incretin  
hormone  synthesis
(104)
. For  the  action  of  GLP-1 on  β cells  it  require  TCF factor   that  β  
cell  proliferation  and  insulin  secretion 
(104)
.  TCF7L2  expression  were  down-regulated  in  
adipose  tissue  of  obese Type  2  Diabetic  people  showing  the  ineffective  action  of  
insulin  due  to  insulin  resistance 
(104)
. Studies  eluded  that  there  is  a  cross-talk  between  
insulin  and  Wnt signal pathway.  
TCF7L2  / TCF4  Protein –Structure:                 
TCF7L2 means  Transcription  factor  7 – like 2 (T-  cell specific  ,HMG- box)  gene  . 
This  gene  encodes  a  high  mobility  group  (HMG)  box  containing  transcription  factor .  
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It  plays  a key  role  in  Wnt  signaling   pathway. Genetic  variants  of  this  Gene  are  found  
to be  associated  with    risk  of   Type 2 Diabetes.  
        Fig: 11 TCF7L2 
 
 
 
 
 
 
 
 
TCF7L2 is made of 596 amino acids (NP_110383.1). It has two conserved domains -  
       - the   CTNNB1_binding domain and   
       - the SOX-TCF_HMG-box domain.   (Fig:12) 
 
 The CTNNB1_binding domain is located from 1 to 236 amino acids. It  is  the  binding  
site  of  β-catenin   to  form  the  active  complex. The  SOX-TCF_HMG-box  domain   is  
located  from  330  to  397  amino  acids. This  domain  binds  to  specific  DNA  motif  and  
regulates  gene  transcription. The    structure  of  TCF7L2  protein  also  shows  a  domain  
for  Groucho  protein. The  amino  acid  sequences  of  HMG  boxes  of  TCF7L1, TCF7L2 
and  TCF7  show  striking  homology.   
 
 In  the  absence  of  Wnt  signaling,  the  HMG-box  TCF  proteins  in  the  nucleus  
forms  complex  with  Groucho  and  C-terminal  binding  protein 1  that  inturn  recruit    
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nuclear  corepressors  like   Histone  deacetylases  (HDACs)   and  acts  as   transcriptional  
repressors   to  the   promoter  region   of  the  Wnt  target  gene.  In  the  presence  of  a  Wnt  
signal  where  beta  catenin  is  accumulated  and   diffuse  into  the  nucleus . Interaction  of  
beta  catenin,  DNA, Groucho and  CtBP-1  to  the  functional  domains  of  human  TCF7L2 
leads  to  activation  of  transcription  of  the  promoter  region  of  Wnt  Target  gene.
(105) 
 
 
Fig:12 TCF7L2 Domain Structure 
 
 
 
 
 TCF7L2 expression  was found  highest  in  Pancreas  followed  by colon, brain, small 
intestine, monocytes and  lungs. Lowest  expression  in  all tissue  and  no  expression  in  T 
and  B  cells.    
 
Expression  and  Functions  of  TCF7L2 gene  in  pancreatic β  cells: 
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 A comprehensive overview of   the   target  genes  for TCF7L2 in pancreatic islets  is   
still   lacking, but it is known to control expression of several genes involved in on cogenesis, 
such as  c-jun, c-myc, Cyclin Dl, and many others. Shu  et  al 
(105)
  study  showed  that   
TCF7L2  has  significant  roll  in  β cell  proliferation, β  cell   apoptosis  and   Glucose  
stimulated  insulin  secretion.  TCF7L2  is  involved  in  pancreas  development   and  
TCF7L2  along  with  SDF-1/CXCR4 transcription  factors -induced  cytoprotection   of   β 
cells. These two mechanism  together  increases  β cell  mass. But  by  TCF7L2  
overexpression  and  TCF7L2  depletion   it  exhibits  opposite  effects  in  human  pancreatic  
beta  cells. This  raises  the  question  if  TCF7L2  is  a  transcriptional  activator  and  not  a  
transcriptional  modulator
(105)
. Finally in a silico study, they  have    identified   that  the    
 
consensus   sequence (WWCAAWG) for   TCF   binding is  in   the proprotein  convertase 1 
(PC1) and PC2 genes . Hence, TCF  factor  is  essential  for   proinsulin conversion  to  mature  
insulin 
(105)
. This is   suggestive of   TCF7L2   role  in insulin processing, and  if  risk  allele  is  
present  this  process  may  be  disturbed. 
 
Expression  and  Functions  of  TCF7L2 gene  in  intestinal  endocrine  cells: 
 
 In  the  Wnt  pathway,  TCF7L2  a  member  of   TCF/LEF  family. is  an  important  
transcription  factor  that   initiates  transcription  at  the  promoter  region  of  proglucagon  
gene  and  express  by  GLP-1  secretion   in  the  intestinal L cells
(105)
. Specific  Wnt  ligands  
stimulate  TCF7L2  gene  expression  in  L  cells. TCF7L2  dependant  signals  were  
implicated  in  the  oncogenesis  of  colorectal  cancer 
(68,106)
 . 
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 Recent  studies  identified  oncogentic  effect  in  breast  cancer
(68,107)
 and  
overexpresion of  tCf7l2  cardiovascular  diseases
(68)
. Studies  showed  the  expression  of  
TCF7L2  in  human  adipocytes.
(105)
              
        
TCF7L2  gene  : 
 The  cytogenetic  location  of  TCF7L2  gene  is  on  the  long (q)  arm  of  
chromosome  10  at  position   25.2 to 25.3.  More  precisely  the  molecular  location  
TCF7L2  gene  starts  from  114,710,009 base pair  from  pter  and  end  at  114,927,437 
basepair  from  pter.  It is made of g 217,429   bases. (Fig:13) 
 
Fig :13 Genomic Structure of  TCF7L2 
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  The Gene structure of TCF7L2  was  determined  by  Duval et al.,(2000). It  
comprised  of  17  exons  of  this  5  were  alternative ( i.e, exon 4  in  5’ end  and  exons  13- 
 
16 in  3’ end )
(68)
. Exon  14  and  15  are  highly  similar  and  exclusively  tissue-specific  so  
that  exon  14  predominates  in  adipose  tissue  and  muscle,  whereas   exon 15 predominates 
islets  and  lymphocytes.
(68)
 Alternate  splicing  sites  were  identified  in  exons 7, 9, 16 and  
17. Alternative  transcriptional   start  sites   in the  promoter  region and  in exon 1 were  
reported and  these  are  rare. This  led  to  the  synthesis  of  many  TCF4  isoforms  having  
short, medium or long C-terminal ends 
(68)
. Such  a  variable  exons  results  in  different  
complex  pattern  of  splicing  and  hundreds  of  potential  protein  isoforms  are  formed.  
This  eluded  the  fact  that  alternative  splicing  leads  to  different  TCF7L2  proteins  
isoforms  that  were  found  to  either  activate  or  repress  the  Wnt  signaling  pathway. How  
TCF7L2  variation  affects  the  gene  function  is  yet  unclear . 
                 
 Micro satellite  are  repeating  sequences   of  2-5 base  pairs  in  DNA called  simple  
sequence  repeat  or  short  tandem  repeats. They  are  distributed  throughout  the  genome  
and  function  as Molecular  markers. Change  in  length  of  Microsatellite  markers  within  
promoter  region  leads  to  quick  change  in  gene  expression  between  generations.  
Micro satellite  markers  within  introns  also  influence  the  phenotype in various disorders 
like Friedrich  Ataxia., Acute  lymphoblastic leukemia , hypertension, osteosarcomas. Linkage  
disequilibrium  is  non- random  association  of  alleles  at  one  or  more  loci. In  a  randomly  
distributed  genotype,  the  amount  of  disequilibrium  depends  on  difference  in  observed  
allele  frequency. When  a  combination  of  alleles  and  genotype  are  found  in  an  expected  
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proportion  then  it  is  said  to  be  in  equilibrium. If  a  large  block  of  linkage  
disequilibrium  is  found  it  is  likely  to  be  a  resource  for  SNP
(112)
.   
                     
 Fig:14 The Diagram Shows the Positions of Seven SNPs and the 
Microsatellite DG10S478 in the Human TCF7L2 Gene 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By  Grant  et  al.(2006)
(108)
,228  microsatellite  markers  were  genotyped   throughout  
10.5Mb  interval  on  10q   in  Icelandic  population  with  Type 2 Diabetes, a  Microsatellite   
DG10S478    that  was   located  within  intron  3    of  the  TCF7L2  gene    was  found  to  be  
associated  with  risk  of  T2DM
(108)
. This study was replicated in Danish  and  US  
population.     The TCF7L2 gene   spans ~ 216kb.  In this region, ~750 single nucleotide 
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polymorphism have  been  identified. The   SNPs  in  the  intron  3   region  of  TCF7L2  
chromosome  were   at  rs7901685, rs7903146, rs12255372, rs7895340, rs11962055, rs 
11196218  and  rs 290487. In  an  international  HapMap  project  data,  TCF7L2  was  found  
to span  several  linkage  disequilibrium [LD]  blocks [main-03-20]. The  SNPs  associated  
with  Type 2 DM  forms  the  largest  LD  block  which  is  spanning  ~65kb. This  LD  block  
begins  from  middle  of  the  intron 3  and  ends  at  the  first  seventh  of  intron 4
(108,109)
.  
Specifically  the  two  SNPs  rs12255372  and   rs7903146   were  in  strong  linkage  
disequilibrium  with  Microsatelite  DG 10S478   and  this    showed  a  robust  association   
with  T2DM
(105)
.  Within  Intron  3, the  non-coding  region   show   SNPs   at   rs12255372 
 and   rs7903146   were found  to  be   associated  with  T2DM .  In  another  study  between  
type 2 DM  and  controls, all  exons of  TCF7L2  gene were  sequenced   and  it  did  not  
show  any  non-synonymous SNP (nsSNP).  This excluded  the  possibility  of   protein  
sequence  polymorphism  leading  to  T2DM  risk.  Then  it  was  postulated   that  the  
regulatory  TCF7L2  genetic  variation  leads  to  change  in  its  target  gene  expression  and  
this  increases  the  susceptibility  for  T2DM
(108)
. (Fig:14) 
 
 
 
 
TCF7L2  gene  polymorphism in  Type  2  Diabetes : 
 
Among  the  various  transcriptional   factors  that  regulate  Proglucagon   gene  
expression, Wnt  pathway  have  showed  a  promising  effect  in  the  transcription  of  
Proglucagon  gene  resulting  in  GLP-1  release  in  intestinal  cells and  also  insulin  
synthesis  and  release  in  beta  cells  of  pancreas.  
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 In  the  homeodomain   β cat/ TCF7L2  that  mediates Wnt  pathway  for  transcription  
of  proglucagon  gene, the  transcription  factor  TCF7L2   exerts   important   regulatory  
action   in  initiating   transcription  and  synthesizing   glucagon- like – peptide -1 in  the  
enteroendocrine  L  cells. The  SNP  of  TCF7L2  gene leads  to  altered  GLP-1  level,  
reduced  postprandial  insulin  secretion
(48) 
 and  enhanced  rate  of  hepatic  glucose  
production  and  shows  strong   association  with T2DM.  
 Interestingly  all  T2DM  susceptible   TCF7L2  SNPs  are  located  within  the intron 3  
region  of  TCF7L2  gene . Hence  it is  most  likely  that  polymorphism  affects   the  Gene  
expression  and  not  its  function  ( Shu et al. 2007, Liu & Habener 2008).  SNP  of  TCF7L2  
is  also  associated  with  Gestational  diabetes, Colorectal  cancer
(110)
. 
 
TCF7L2  gene  polymorphism: 
    
                        
 
 
 
 
 
 
 
The  SNP  at  rs 7903146  is  having  strong  association  with  T2DM  in  many  
population. There  is  no  convincing  association  was  shown  between  T2DM  risk  
genotypes  and  the  total expression  of  TCF7L2   or  the level of expression  of  any TCF7L2 
splice variant. Various hypothesis  identified  are   
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1. A   positively  significant   correlation  was  found  between   exon 4 incorporation  in  
pancreatic islets  and  hemoglobin A1c levels . Though this need further research, it   
reveals a link between  TCF7L2  splicing varients and plasma  glucose  levels. 
Notably, the rs7903146 polymorphism   is located within intron 4   which is in close 
proximity to exon 4
(68)
. 
2. A  nominally  significant  difference  was  observed  in  genotype  dependant  relative  
expression  of  targeted  transcripts  using  assays  for  exons  14 to 16
(68)
. 
3. TCF7L2  gene  carring  the  risk  allele  T  at  rs  7903146  shows  an  E4BP4  binding  
site  and  two  CDX1  binding   sites  in  the  TCF7L2  protein  domains  that  is  
absent  in  the  common  C  allele  carrying  genotype. This  hypothesized  that  
E4BP4, CDX1  and  some  micro RNAs  in  the  intron3   transcribed  with  host  gene  
or  independently  in  intron 3 of  TCF7L2  leads  to  a  TCF7L2 variant  that  
predisposes  to  T2DM
(68)
. 
4.  The  alternative  splice  sites  in  exon  7 and  9  are  highly  conserved  among  
species. Exon 9 encodes the recognition  site  for  TLE/Groucho domain. Alternative 
splicing  of  this  domain  did not  interfere with  TCF7L2  action 
(68)
. 
 
Study  shows  that  inclusion  of  exon 4  found  to  severely  impair  TCF7L2- 
dependant promoter  activation, even  though  specific  interactions  of  TCF7L2  binding  
partners  with  the  exon 4 – encoded  part  of   the  protein  have  not  been  demonstrated 
(68)
. 
Whether  this  is  due  to  un characterized  interactions  or  due  to  medium  or  long  range  
protein  structural  effects  remains  to  be  elucidated. 
 Due  to  SNP  of  TCF7L2  gene,  a  different  splice  variant  of  TCF7L2 isoform  
were  synthesized. Such SNPs showed  strong  association  to  T2DM.  
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TCF7L2  an  important  transcription  factor  that  initiates  transcription  of  promoter  
region  of  proglucagon  gene  in  the  presence  of  Wnt  ligands  that  activates  Wnt  pathway 
leads  to  GLP-1  production  in  the  intestine,  insulin  synthesis  and  secretion  in  the  β 
cells  of  pancreas  and  suppression  of  glucagon  secretion  in  the α cells  of  pancreas. 
 
 In  T2DM   defective  insulin  synthesis, defective  glucose  stimulated  insulin  
secretion  and  increased  hepatic  glucose  production  were  contributed  due  to  defective  
GLP-1  secretion. The  genotype  showing  SNP  at  rs7901436 and rs12255372 for  TCF7L2  
gene which affects the transcription of GLP-1  production,   has  increased   incidence  of 
T2DM  in  various  population.  
 
As  TCF7L2  the  transcription  factor,  has  a  significant  effect  in  insulin  synthesis  
and  secretion   through  GLP-1  and  independently,  it  is  hypothesized  that  TCF7L2  gene  
polymorphism  at  rs7901436  and rs12255372 could  be  a  genetic  marker   for  Type 2 
Diabetes. 
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MATERIALS AND METHODS 
The study  was  performed  during  the  period  April  2014 – August  2014  as  case-
control  study. Study  population  had  known Type 2 Diabetic subjects as cases and controls  
were  apparently  healthy  subjects . 
STUDY POPULATION: 
CASES GROUP: 
This group consisted of 44 Type 2 Diabetic patients who were attending  OP in the 
Department of Diabetology, Govt. Kilpauk Medical College & Hospital(GKMH), Chennai. 
Type 2 Diabetes was considered to be present if an individual had a history of T2DM or if the 
fasting blood sugar  > 126mg/dl, postprandial blood sugar  > 200mg/dl  and  HbA1c  > 6.5
(22)
. 
INCLUSION  CRITERIA: 
Only patients with known Type 2 Diabetes Mellitus were included in this study. 
EXCLUSION CRITERIA: 
•  Patients with Type 1 Diabetes, 
•  Patients with impaired blood glucose level 
•  Those with other endocrine disorders. 
 
CONTROLS GROUP: 
          This group consisted of 44 Controls who were chosen from patients attending general 
Outpatient Department(OPD) at the  GKMH, Chennai. Patients were considered controls if an 
individual had no history of Type 2 Diabetes or if the fasting blood sugar <100 mg% , 
Postprandial blood sugar <140mg%  and  HbA1c <5.6
(22)
.  
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The study was approved by the Institutional Ethical Committee of GKMC, Chennai. 
After a full explanation of the study a written informed consent was obtained from each 
participant . 
SAMPLE COLLECTION: 
Under sterile condition, 5ml of peripheral venous blood as a postprandial sample ( 2 
hours after the first bolus of morning breakfast ) was withdrawn using sterile disposable 
syringes  from all the study subjects. Then 2ml of this blood was transferred to EDTA tube for 
HbA1c estimation which was assayed on the same day itself. Remaining 3 ml of blood was 
transferred to another EDTA tube and mixed thoroughly. 
BUFFY COAT SEPARATION: 
The EDTA tube was centrifuged at 2500 rpm for 20 minutes. Buffy coat was extracted 
carefully and transferred to 2ml eppendorf. From this buffy coat DNA was extracted using 
Genomic DNA Minispin Prep kit from HELINI. Plasma separated was aliquoted and stored at 
-20
*
C  for  analysis of  GLP-1,  Insulin,  Blood glucose,  Urea,  Creatinine,  Total.Cholestrol  
and   HDL.   
BIOCHEMICAL MARKERS: 
        Glucogon like peptide-1 and Insulin were determined by enzyme linked immunoassay 
method. Total cholesterol (TC) and High Density Cholestrol(HDL-c) were determined using 
Kits in  Robonic auto analyser at central biochemistry laboratory, GKMH, Chennai. Non-HDL 
cholesterol was calculated using formula. 
DNA MINIPREPARATION KIT: - From Helini Biomolecules, Chennai. 
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Kit method  allows  rapid  preparation  of  high quality genomic DNA. This method is 
suitable for  DNA  extraction  from  blood  collected  in  Heparin or  EDTA tube  or  whole 
blood treated with citrate  or  buffy coat. The  principle  is  based  on  exclusive  silica  based  
membrane  technology  in  the  form of  convenient spin column. 
PRINCIPLE : 
Cells on short incubation with proteinase K in the presence of chaotropic salts, get  
lysed and immediately inactivates all nucleases. The Purefast purification filter tube  
prepacked  with  special  glass  fibres  allows  selective  binding  to cellular nucleic acids .To 
remove the contaminating  cellular  components  and  purify the  bound nucleic acids  it  
undergoes  a  series  of  rapid ‘spin and wash’ steps. Finally the nucleic acids  are  released  
from  glass fibre by low salt elution.  
COMPONENTS OF THE KIT: 
· Proteinase K 
· Lysis buffer 
· Wash buffer I ( fresh  70%  ethanol ) 
. Wash buffer  II  (fresh  70%  ethanol) 
· Isopropranolol 
· Elution buffer 
· Spin columns with collection tubes. 
 
PROCEDURE for DNA extraction and purification: 
BLOOD / BUFFYCOAT: 
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A nuclease free 1.5 ml microcentrifuge tube is taken and 200µl of blood or  buffy coat  
followed by following steps. 
1. 400µl of  lysis buffer was  added  and  mixed  well immediately  by  inversion  or 
gentle vortex. 
2. 20µl of Proteinase K was added and vortexed  for 10 seconds then  allowed  for 
incubation  at 56
*
C for 15 minutes. 
3.  After incubation 200µl of  isopropanolol  was  added and mixed well by inverting 
several times. 
4. The entire sample is pipetted into the PureFast spin column and centrifuged at 
12000 rpm for 1min. The flow-through was  discarded and placed the column 
back into the same  collection tube. 
5. 500µl of Wash buffer I was added  to the PureFast spin column and again 
centrifuged at 12000 rpm for 1min. Then the flow-through was discarded and 
placed the column back into the same collection tube. 
6. 500µl Wash buffer II was added to the PureFast spin column and again 
centrifuged at 12000 rpm for 1min. Then the flow-through was discarded and 
placed the column back into the same collection tube. 
7. The step with Wash Buffer II was repeated once again.Then the flow-through was 
discarded and placed  the spin column back into the same collection tube and  did 
empty centrifuge at 13000rpm for 2 min. This step is done to avoid residual 
ethanol. 
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8. The PureFast spin column was transferred into a fresh 1.5ml microcentrifuge tube. 
Then 60µl of the prewarmed Elution Buffer was added at  the centre of Purefast 
spin column  membrane. Take care not to touch the membrane with the pipette tip. 
9.  Incubated at room temperature for 2 mins and centrifuged at 13000rpm for 1min. 
10.  The column was discarded and the  purified  DNA extracted was  stored at -20
*
C 
for future use.  
  
IDENTIFICATION: 
            Extracted DNA was identified by 1.2% agarose gel electrophoresis  by comparing with 
a known molecular weight, 100 bp DNAladder  or  Lambda EcoRI / Hind III DNA  marker  as  
depicted in (Fig15) 
CONCENTRATION OF  EXTRACTED DNA: 
• Concentration of extracted DNA was estimated using UV spectroscopy at 260nm.The 
adsorbance at 260nm was 0.0066.  
Concentration was calculated usingthe formula: 1 OD is equivalent to50µg/ml 
Conc. of DNA = absorbance × 50µg/ml × dilution factor 
                              = 0.0067 × 50 × 60 
                              = 20 ng / µl 
• Purity of extracted DNA was assessed by 260/280 ratio and it was found to be > 1.7. 
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IN  TCF7L2  GENE  FOR  rs7903146: 
POLYMERASE CHAIN REACTION: 
In TCF7L2 gene for rs7903146, PCR product with  578bp fragment was amplified 
using  the extracted  DNA as template  and  its  forward, reverse primers as follows. 
Forward primer – 5’
 
– CTGTTTCTTGCTTAGTCACTTTCTG – 3
’ 
Reverse Primer – 5’ – CTTTCACTATGTATTGTTGCCAGTC – 3’ 
 
PRIMER  RECONSTITUTION:  
• Primers are supplied in lyophilized form. 
• Fresh  1X  TAE  buffer  is used to prepare 100X concentrations . 
Forward   primer: 
Step 1: To prepare  forward  primer  of  concentration   100 pmoles/µl   solution  
• 262 µl  of  1X  TAE  buffer  is  added  to  lyophilized  primer. 
Step 2: From this stock solution, 10X concentration is prepared as working solution for PCR. 
• For  200µl  of  10X  concentration  =  10µl  primer  +  190µl  distilled   water.  
 
Reverse  primer  : 
 
Step 1: To  prepare  forward  primer  of  concentration   100pmoles/µl   solution 
• 344 µl  of  1X  TAE  buffer  is  added  to  lyophilized  primer. 
Step 2: From this stock solution,  10X concentration is prepared as working solution for PCR. 
• For  200µl  of  10X  concentration  =  10µl  primer  +  190µl  distilled   water 
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MASTER MIX: 
Heleni   2X PCR   master mix in the following composition was used. All  basic  
components  needed  for  PCR  were in the Master mix. 
• Reaction buffer consisted of Tris Hcl - 10mM at pH 8.3, KCl - 50mM 
• MgCl2 - 2mM acts as catalyst. 
• dNTP’s were used in a concentration of  200µM each. 
• Taq polymerase in a concentration of 1.25 U. 
• Primers were used in a concentration of 10pmols and DNA was used in a 
concentration of  100ng. 
PCR was carried out in a reaction volume of 20 µl  with the following  components: 
• PCR master mix – 10 µl 
• Forward primer – 2.5 µ l 
• Reverse primer – 2.5 µl 
• DNA – 5.0µ l 
• Total - 20 µl 
Amplification was carried out in an CYBERLAB SMART  PCR-PRO thermal cycler 
with the  following cycling conditions. 
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PCR – RFLP ASSAY done: 
The  temperature  settings  for  PCR  amplification as  follows: 
• Initial denaturation  at  95*C -  5mins 
• 34 cycles of 
- Denaturation            – 95*C – 30 secs 
- Annealing                  - 56*C  – 30 secs 
- Extension                   - 72*C –  30 secs 
 
• Final extension   at      72*C -  9 min. 
 
The  amplified product – amplicons of 578 bp  for rs7903146 was identified by  
2% agarose gel electrophoresis by comparison with a known 100 bp DNA ladder. (Fig16) 
AGAROSE  GEL ELECTROPHORESIS: 
• PCR product is run on 2% agarose gel in a 30ml agarose cast as follows:  
0.6g of   agarose is weighed and dissolved in 30ml of 1X TAE buffer with a pH of 8.2. 
• It is microwaved for 60 secs, cooled and 1.5 µl of ethidium bromide (10mg/ml) is  
added. 
•  It is poured into a cast and allowed to solidify for 45 min before it is kept in  the 
electrophoresis tank. 
• 10 µl of  PCR product is loaded onto wells and 4 µl of 100bp DNA ladder is loaded onto 
single well as a marker. 
• It is electrophoresed at  8V/cm  for  45min  and  visualized  under  UV 
illumination.(fig16) 
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RESTRICTION DIGESTION OF PCR PRODUCTS: 
TCF7L2 polymorphism  at rs7903146  was detected by digestion of the 578 bp PCR  
amplified product with the Hpy-CH4III  restriction enzyme followed by run in 
3.0% agarose gel electrophoresis. 
Enzyme  Taal ( HpyCH4III): 
• Concentration :  200U / 20 µl. 
• 1X  Tango  buffer :  1 ml 
Principle of Hpy-CH4III  enzyme digestion: 
• T allele does not have the restriction site hence will yield a 578bp fragment 
• C allele has the restriction site, hence gets cleaved to give 400bp and 178bp fragments. 
• Heterozygous individuals (CT) have 578 bp, 400bp, 178bp  fragments. 
• Analysis was done using a 100bp DNA ladder. 
• The genotype was confirmed by gene sequencing from a random sample. 
Procedure for Restriction Digestion: 
• 20µL of PCR product is aliquoted in an eppendorf, 3µl of  1X  Tango buffer, 6µl  of  
Dist. Water  and 10U  (1µl ) of  Hpy-CH4III  enzyme is  added  making  a  final volume  
of  30 µl. 
• The entire procedure is carried out in  ice. The contents are mixed thoroughly. 
• The eppendorf is then placed in a 65
*
 C waterbath for 2 hours. 
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•   Restriction digested product is subjected to 3% agarose gel electrophoresis for 
genotyping. 
Procedure for Gel electrophoresis: 
•  Restriction Digestion product is run on 3.0% agarose gel in a 30mL agarose cast as 
follows: 0.90g of agarose is weighed and dissolved in 30mL of  1X TAE buffer with a 
pH of 8.2. 
• It is microwaved for 120 secs, cooled and 1.5µL of ethidium bromide (10mg/mL) is 
added. It is poured into a cast and allowed to solidify for 45 min before it is kept in the 
electrophoresis tank. 
• 20µL of Restriction Digestion product is loaded onto wells and 4µL of 100bp DNA 
ladder is loaded onto single well as a marker. It is run in electrophoresis tank for 
45min and visualized under UV illumination.(Fig.17).  
     Then  the genotypes were identified by comparing the  various fragments  visualized  
to 100 bp DNA ladder. The visualized   images were Gel documented in LIFE Technologies  
Gel-doc instrument and stored for future use.  
IN TCF7L2 GENE For rs 12255372,  
ALLELE   SPECIFIC  PCR- ARMS  ASSAY
(147)
 done. 
Primers : 
In TCF7L2 gene for rs 12255372, PCR product of G allele with 271 bp fragment was 
amplified using the extracted DNA as template and its forward, reverse primers as follows.  
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Forward primer – 5’
 
–GAGGCCTGAGTAATTATCAGAATATGATC– 3
’ 
Reverse Primer – 5’ –AGTCATTTGATGATTGTTTTGTTAATGGC– 3’ 
In TCF7L2  gene for rs 12255372, PCR product of T allele with 181 bp fragment was 
amplified using the extracted DNA as template and its forward, reverse primers as follows. 
Forward primer – 5’
 
–CTGCCCAGGAATATCCAGGCAAGAGTT– 3
’ 
Reverse Primer – 5’ –GAGAGAGTGCACTAAAGACGTGGATTCT– 3’     
The  temperature  settings  for  G and T  Allele  specific  PCR  amplification which 
was standardized in our laboratory are  as  follows: 
• Initial denaturation  at  95*C -  5mins  
• 34 cycles of 
- Denaturation             – 95*C – 1  mins 
- Annealing                  - 64*C  – 1  mins 
- Extension                   - 72*C –  1  mins 
• Final extension   at      72*C -  5  mins. 
The  amplified   product – amplicons  of  271 bp  for  G allele and 181 bp for T allele, 
at the rs 12255372 was identified by 2% agarose gel electrophoresis by comparison with a 
known 100 bp DNA ladder. (fig:18) 
AGAROSE  GEL ELECTROPHORESIS: 
• PCR product is run on 2% agarose gel in a 30 ml agarose cast as follows: 0.6g of   
agarose is weighed and dissolved in 30ml of TAE buffer with a pH of 8.0. 
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• It is microwaved for 60 secs, cooled and 1.5 µl of ethidium bromide (10mg/ml) is  
added. It is poured into a cast and allowed to solidify for 45 min before it is kept in  
the electrophoresis tank. 
• 10 µl of  PCR product is loaded onto wells and 4 µl of 100bp DNA ladder is loaded 
onto a single well as  marker. 
•  Electrophoresis  done  at 100v  for  45min  and  visualized  under  UV illumination. 
 
• Then  the genotypes were identified by comparing the  various fragments  visualized  
to 100 bp DNA ladder. The visualized   images were Gel documented in  Life sciences 
technology- gel-doc instrument and stored for future use. The genotype was confirmed 
by gene sequencing done on a random sample. 
 
The biochemical parameters undertaken for the study were determined using the 
following methodologies. 
• Calibrated  using  Randox  Calibrator  Lot  no:  2350 – 770UN.  
• Randox control  lot  no: 768UN Level  2 and lot no:501UE Level 3 were used. 
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Estimation  of  Plasma  Glucose : 
Method:  Glucose Oxidase  peroxidase (  GOD / POD )( End point Test ) 
Kit  used  :  Erba 
Principle : 
                                           Glucose  Oxidase 
Glucose  +  O2  +  H2O                                                                  Gluconic acid     +    H2O2   
                                         Peroxidase            
      pink  coloured   
H2O2   +  Phenol  + 4AAP                                                     Quinoneimine  complex + 2H2O 
Intensity  of   pink  coloured  Quinoneimine  complex  is  proportional  to  glucose  
concentration  in  the sample . Absorbance  was  measured  at  505  nm. 
Reagents  composition 
Reagent -1 : Enzyme  reagent 
Glucose  oxidase - >  20000U/L 
Peroxidase  - >   2000U/L 
Phenol   - 10 mmol/L 
Phosphate   buffer - 200 mmol/L 
Glucose  standard -  100  mg/dl 
Procedure : 
       To  1000µl  of  working  reagent  10µl  of  plasma  was  added and allowed  for  
incubation  for  15  mins  at  37
*
C. 
Referance  range : 
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        Postprandial  plasma  glucose    90-140 mg/dl. 
Estimation  of blood Urea: 
Method:  Urease  - GLDH ( kinetic  UV test ) 
Kit  used : Accucare 
Principle: 
Urea  is  hydrolysed  in the presence  of  water and  Urease   to  produce  ammonia  
and  carbondioxide .  The ammonia  produced  combines  with  α- oxoglutarate  and  NADH  
in the  presence  of  glutamate  dehydrogenase  to  yield  glutamate  and  NAD. 
                                           Urease 
    Urea  +  H2O                                        2NH4  +  CO2 
                                                                                                            GLDH 
NH4   +  NADH  +  H
+  
+ 2-oxoglutarate                                  Glutamate  +  NAD
+ 
The  initial  rate  of  reduction  in  absorbance  is  directly   proportional  to  the  urea  
concentration  in  the  sample. Absorbance is measured at  340  nm. 
Reagent  composition: 
Reagent   I        :  Buffer  reagent 
Reagent  II        : Enzyme  reagent 
Urea  standard  :  50 mg/dl 
Reagent  preparation: 
Mix  4  parts  of  Buffer  reagent  with  1  part  of  Enzyme  reagent  and mix gently. 
Procedure: 
Took  1000µl   of  reconstituted  reagent  and  added  10µl  of  plasma  and absorbance  
measured immediately  at  340 nm. The  rate  of  reduction  after  30 secs  and  60 secs is  
proportional  to  concentration  of  Urea. 
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Referance  range: Serum / Plasma   Urea  15 – 39 mg/dl. 
 
Estimation  of  Creatinine: 
Method :   Jaffe’s  method (  Picrate  method )( Initial  rate  method) 
Kit  used:   Erba 
Principle  : 
Creatinine  reacts with  alkaline  picrate  to  produce  an  orange – yellow colour ( 
Jaffes  reaction).  Absorbance  of  the  colour  is  directly  proportional  to  concentration  
creatinine  in the  given  sample. Absorbance measured at  500nm. 
Reagent composition: 
Reagent 1 :  picric acid  reagent 
Picric acid    -    25.8 mmol/L 
Reagent  2 : sodium  hydroxide  reagent  
Sodium  hydroxide – 95 mmol/L 
Creatinine  Standard   -   2mg/dl( 0.166 mmol/L) 
Reagent  preparation : 
Mix  equal  volumes  of  reagent 1  and  reagent 2. Wait  for  15 mins  before  use. 
Procedure: 
Took  1000µl  of the reconstituted  reagent  and  added  100µl  of  the  sample  and mix and  
read immediately. Difference  between   initial  absorbance  after  20 secs  and  final  
absorbance  after  80 secs of  mixing  were  measured. 
Referance  range: 
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Male     :  0.6 – 1.1 mg/dl,   
Female  :  0.5 – 0.9 mg/dl. 
 
Lipid profile: Estimation of Cholestrol: 
Method: Cholesterol Esterase – Cholesterol Oxidase   CHOD-PAP ( End point test) 
Kit: Erba 
Principle: 
                                          Cholesterol Esterase 
Cholesterol Ester + H2O                                         Cholesterol+ Fatty acids 
                                        Cholesterol Oxidase 
Cholesterol + O2                                                       Cholestenone + H2O2 
                                                                     Peroxidase 
H2O2 + Phenol + 4- Aminoantipyrine                                       Red Quinoneimine  dye+ 4H2O 
 
The intensity of the red complex (red Quinoneimine) is directly proportional to the 
concentration of cholesterol in the sample  which is measured at 500nm. 
Reagent composition : 
Buffer ( pH – 6.4 )     -   100mmol/L 
Cholestrol Oxidase     -    > 100 U/L 
Cholestrol  esterase   -     > 200 U/L 
Peroxidase                 -     >3000U/L 
4 – Amino antipyrine  -   0.3 mmol/L 
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Phenol                         -   5mmol/L 
Cholesterol  standard      -    200mg/dl 
 
Procedure: 
To 1000µl  of  the reconstituted  reagent, 10 µl of plasma is added and reading is taken 
after  5  mins  of  incubation at 37
*
C. 
Reference Values: 
Cholesterol: 150-260 mg /dl. 
 
Estimation of HDL Cholesterol: 
Method : Direct, Enzymatic colorimetric 
Kit used : Spinreact 
Principle: 
It is direct determination of serum HDL-cholestrol. The assay takes place in 2 steps: 
Step 1:  Elimination  of  lipoprotein  no-HDL 
                               cholesterol   esterase 
Cholestrol esters                                             Cholestrol   +  Fatty  acids 
                                 cholesterol  oxidase 
Cholesterol  +  O2                                                               4- Cholestenone  +  H2O2 
                                          Catalase 
 2H2O2                                                                                                 2H2O    +   O2 
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Step 2 :  Measurement  of  HDL c 
                               cholesterol   esterase 
Cholestrol esters                                             Cholestrol   +  Fatty  acids 
                                   cholesterol  oxidase 
Cholesterol  +  O2                                                               4- Cholestenone  +  H2O2 
                                                                         peroxidase 
2H2O2   +  HDAOS  +4-Aminoantipyrine                                           Quinonimine  +  4H2O 
The intensity  of  the  color formed  is  proportional  to  HDLc  concentration  in  the  
sample. Absorbance is measured  at  600  nm. 
Reagent composition: 
Reagent 1: 
N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline (HDAOS)   -  0.7 mM 
Cholesterol  esterase       >  800  U/L 
Cholesterol  oxidase       >  500  U/L 
Catalase                          >  300  U/L 
Ascorbic  oxidase           >  3000  U/L 
Reagent  2: 
4- Aminoantopyrine ( 4-AP)    -   4mM 
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Peroxidase                                >  3500U/L 
Calibrator : 
HDLc     -        56.5mg/dl 
Procedure : 
Reagent 1 and  reagent  2 are  kept  seperatly   in  auto analyser  with  the  following  
assay  parameters: 
Assay type                     : 2 point 
Primary wavelength      : 600 nm 
Secondary wavelength  : 700 nm 
R-1 volume : 270, 
 R-2 volume : 90 
Reaction direction : increasing,  
Sample volume : 3 µl,  
Calibration: straight 
Reference Values: 
Adult  male           : 35.3 – 79.5 mg /dl 
Adult  female        : 42.0 – 88.0 mg / dl 
 
 
Calcualted  Non- HDLc: 
Non HDLc  =   Total  cholesterol - HDLc 
Reference range :(Cardio Metabolic Risk- CMR) 
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• Diabetes  with  CMR  risk  factor: 
Non HDLc  < 130 mg/dl 
• Diabetes  without  CMR  risk  factors: 
Non HDLc  < 100 mg/dl.   
 
Estimation of Glycated hemoglobin (HbA1C) 
Method: High Performance Liquid Chromatography (HPLC)  
HbA1C  test is done to measure the level of glycated hemoglobin in the blood and  
reported with eAG- “Average  Glucose”. This test shows the mean blood glucose level of the 
patient for  the  past  2 -3 months. 
Principle:  
Done by Chromatographic assay using BIORAD D10 HPLC instrument, ion exchange 
column to separate HbA1c molecules from other hemoglobin molecules. The HbA1c is 
estimated by the ratio of HbA1c peak area to the total Hb peak areas as given in the equation  
eAG(mg/dl) = 28.7 x A1C – 46.7 
Reference Range  : Hemoglobin A1C (%)  
 ADA criteria - HbA1c  
Normal- <  5.6% 
Impaired - 5.7 -6.4% 
Diabetic  - >  6.5% 
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Estimation  of  Glucogon like peptide -1: 
Method :  Competitive  Enzyme  Immunoassay 
Kit :  RayBiotech
R
EIA 
Principle: 
The  microplates  are  precoated  with  anti-rabbit secondary  antibody. The  plate  is  
incubated  with  anti GLP-1 antibody  . During the  incubation  time  both  biotinylated  GLP-
1 peptide  and  peptide  standard  or  targeted  peptide  in  samples  react  competitively  with  
the  GLP-1 antibody. Bound or Uncompeted  biotinylated  GLP-1   peptide   interacts  with  
streptavidin – horseradish peroxidase (SA-HRP)  and  catalyzes  a  color  development  
reaction. Colorimetrically  the  intensity  measured   is directly proportional to the amount of 
biotinylated peptide –SA –HRP complex and  inversely proportional to the amount  of  GLP-1 
peptide  present  in the standard or samples.  With  known  concentration  of  GLP-1  peptide  
a  standard  curve  can  be  established  from  which   the  concentration  of  GLP-1 peptide in 
the  samples  are  calculated  accordingly.  
Kit component: 
1. GLP-1 Microplate :  96 wells  coated with secondary  antibody. 
2. Anti-GLP-1 polyclonal antibody  :  2 vials, 5µl/vial 
3. 1x  Assay  Diluent  E: 2 vial, 25 ml ( diluents  for  both  standards  and  samples) 
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4. Standard  GLP-1 Peptide : 2 vials, 10 µl/vial 
5. Biotinylated  GLP-1 peptide : 2 vials, 20 microlitre/vial   
6.  Positive  control : 1 vial, 100µl. 
7. TMB one-step substrate reagent :12 ml of 3,3’,5,5’-TetraMethylBenzidine  in  buffered 
solution. 
8. Wash  buffer  concentrate ( 20x): 25 ml 
9. Stop  solution :8ml of 0.2 M sulfuric acid. 
10. HRP – streptavidin concentrate : 600µl, 250x concentrated  HRP- conjugated streptavidin 
 
Reagent  preparation: 
Kit  reagents  must  be kept on ice during preparation.  
1. Anti-GLP-1 polyclonal antibody concentrate: 
Centrifuge the vial .Prepared  polyclonal  antibody  concentrate  add 50µl of 1x Assay 
Diluents E and pipette up and down to mix gently. 
2. Anti-GLP-1 antibody working solution : 
Polyclonal Antibody concentrate should  be diluted 100 folds with 1x Assay Diluent E  
3. Biotinylated  GLP-1  with final concentration  10pg/ml: 
The  vial  is  centrifuged  and  add  5µl of  biotinylated  GLP-1 to  5ml  of  1x   Assay  
Diluent E . Pipette up and down to mix gently. 
 
4. Standard  preparation : 
 With  the  following  concentrations  6 microtubes  are  labeled as 1000 pg/ml, 
100pg/ml, 1pg/ml, 0.1 pg/ml,0 pg/ml. 
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 Except  for  1000pg/ml tube,  add 450 µl of biotinylated GLP-1 solution into each tube. 
 Standard-1 ,  1000pg/ml  GLP-1 stock solution: 
In 1000pg/ml  labeled tube, added 8 µl  of  standard  GLP-1 + 792 µl of  10pg/ml        
biotinylated  GLP-1. 
 Standard -2, 100pg/ml : 
In  100pg/ml  labeled  tube having 450 µl of  biotinylated GLP-1  added  50 µl of GLP-
1 stock solution  and  mixed  thoroughly. 
 Standard – 3, 10pg/ml  : 
In 10pg/ml labeled  tube having 450 µl of  biotinylated GLP-1  added  50 µl of 
standard 2 solution and mixed thoroughly. 
 Standard – 4, 1pg/ml: 
In 1pg/ml labeled  tube having 450 µl of  biotinylated GLP-1  added  50 µl of standard  
3  solution and mixed thoroughly. 
 Standard – 5, 0.1pg/ml : 
In  0.1pg/ml  labeled  tube  having  450 µl of  biotinylated GLP-1  added  50 µl of 
standard  4  solution  and  mixed  thoroughly. 
 Standard – 6, 0pg/ml : 
In 0 pg/ml labeled tube  has only  450 µl of  biotinylated GLP-1  of 10 pg/ml 
concentration with 0pg/ml of GLP-1 concentration. 
5. 10 fold diluted  biotinylated  GLP-1 : 
2 µl of  biotinylated GLP-1   +  18µl of 1x Assay Diluent E. 
 
6. 2  fold  diluted  Positive  control preparation : 
-Centrifuge  the  positive control  vial  -100µl. 
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-add  101µl  of  1X  Assay  Diluents  E and  add  2µl  of  10 fold  diluted  biotinylated  
GLP-1 to the  100µl  of  positive  control.  
7. 20X  wash  buffer  concentrate – 20ml: 
Prepared  400ml  of  1X wash  buffer – 20ml of  wash  buffer  concentrate  + 380ml  of  
deionised  water . 
8. Sample  preparation : 
Add  2.5µl  of  10 – fold  diluted  biotinylated  GLP-1  to  247.5 µl  of  sample and  
mix  thoroughly. 
9. HRP – streptavidin  conjugate  concentrate – 250X  - 600µl : 
Short  spin  the  vial  . Diluted  250 fold  with  1X  Assay  Diluent E. 
Procedure: 
Keep  the  prepared  reagent  in an  ice  tray. 
• Secondary  antibody  coated  GLP-1  microplate  with  96  wells  brought  to  room  
temperature.100µl  of  anti-GLP-1  antibody  added  to  each  well .Incubated  at  room  
temperature  for  1.5 hrs  with  gentle  shaking  of  1-2 cycles  /sec. 
• After  1.5 hrs  of  incubation,  the  solution  in  wells  are  discarded  and  washed  4 
times  with  1X  wash  buffer in  an  automated  plate  washer. For  complete  removal 
of  wash  liquid  , plate  is  inverted  and   blooted  against  filter  paper. 
• Add  100µl of  standard, positive  control and  sample into  appropriate wells.cover  the  
wells  and  incubate at RT for 5hrs with gentle  shaking 1-2 cycles/sec. Discard the  
solution  and  wash . 
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• Prepared streptavidin solution 100µl added  to  each well  and  incubate at RT  for 
45mins with gentle shaking. After 45mins discard  the  solution and wash. 
• Add  100µl  of TMB one-step substrate reagent to each well and  incubate for 30mins 
at RT in dark with gentle shaking.   
• After 30mins 50µl of stop solution added to each well and absorbance  measured at 
450nm immediately in  Elisa  reader. 
 Sensitivity : 
The  minimal concentration is 1.17pg/ml. 
Specificity : 
This kit has no cross reactivity with any of cytokines tested – Ghrelin , angiotensin II, 
Detection range : 
0.1-1000 pg/ml 
STANDARD DATA 
Standards CONC (pg/ml) OD 450 
S0 1000 0.374 
S1 100 0.537 
S2 10 0.626 
S3 1 1.018 
S4 0.1 1.294 
S5 0 1.262 
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Estimation  of   insulin level: 
Method: Enzyme linked  immunoassay 
Kit: DRG diagnostics 
Principle: 
This is a solid  phase  enzyme – linked  immunosorbent assay(ELISA) based  on sandwich 
principle. The  monoclonal  antibody  coated  on  microtitre wells  bind  to unique  antigenic 
site  on  the  insulin  molecule. On  incubation  endogenous insulin  that  bound  to  
monoclonal antibody, reacts  and  binds to  enzyme  conjucate - anti-insulin  antibody  
conjugated  to  biotin. After unbound  conjugates are  washed, Enzyme  complex - 
Streptavidin –HRP Complex  binds  to biotin anti insulin antibody. The  amount of bound 
HRP complex is  proportional to concentration of insulin in the sample. Having added the  
substrate  solution, the intensity of  colour developed is  proportional to  the  concentration of  
Insulin in the patient sample.  
REAGENTS :  
• Microtitre wells- 96 wells ,coated with monoclonal anti-insulin antibody. 
• Standards – 0, 6.25,12.5, 25, 50, 100 µIU/ml 
• Enzyme conjugate – Monoclonal anti-insulin conjugated to biotin. 
• Enzyme complex- Streptavidin – HRP-complex 
• Substrate solution – Tetramethylbenzidium (TMB) 
• Stop solution - 0.5M sulphuric acid   
• Wash Buffer Concentrate:  40X 
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Wash buffer concentrate, 30ml is mixed with 1170ml  of deionized water to prepare 
wash buffer of final volume 1200 ml. Keep it at the room temperature. 
ASSAY PROCEDURE  
Bring all reagents to room temperature, before assay.  Proper mixing of reagent  is 
done before assay. 
1. Desired wells are secured into the holder. 
2. Using new disposable tips, 25 µl  of standards, control and patient’s samples are  
Pipetted into desired wells.   
3. Insulin Enzyme Conjugate of 25µl  is added into all wells.  
4. Good mixing is done for about 10 sec by gentle shaking. 
5. For about 30 minutes incubation done at room temperature. 
6. Using automated plate washer washing done . 400 µl of wash buffer is used to Wash 
wells three times .  Blot with absorbent paper.  
7. HRP enzyme complex 50µl added to each well. 
8. Incubated for 30 mins at RT. 
9. Using automated plate washer washing done . 400 µl of wash buffer is used to Wash 
wells three times.  Blot with absorbent paper.  
10. TMB substrate of about 50 µl are dispensed to all wells. 
11. Incubate for 15 minutes at room temperature. 
12. 50µl of stop solution is dispensed to all wells. Gentle Shaking to mix the content in the 
solution.  
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13. By ELISA Reader at 450 nm optical density absorbance is read within 10 minutes after 
adding the stop solution.  
CALCULATION OF RESULTS: 
The standard curve is constructed as follows: 
1. A standard curve is constructed, by  plotting  insulin  standards   absorbance value  
along the vertical axis versus the insulin standard concentrations in µIU/ml along 
horizontal axis . 
2. Unknown sample concentration is read from the standard curve. Record the value for 
each control or unknown sample.  
3. Value above the highest point of the standard are retested after diluted or reported as > 
100µl /ml. 
 
STANDARD DATA 
Standards CONC (µIU/ml) OD 450 
S0 0.000 0.063 
S1 6.250 0.282 
S2 12.50 0.593 
S3 25.00 1.363 
S4 50.00 2.235 
S5 100.00 2.308 
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PERFORMANCE CHARACTERISTICS: 
Assay dynamic range -1.76 to 100µIU/ml. 
Sensitivity:   
This is measured by calculating the mean plus 2 Std Deviation  of the standard zero 
point tested twenty times in the same run and was found as 1.76µIU/ml. 
Specificity:  
The antibodies used in the kit cross react with porcine insulin and bovine insulin 
(>100%) but did not cross react with  human proinsulin . 
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RESULTS 
                              
In  Chennai  suburban  population, 44  Type 2 Diabetic  cases  and  44  apparently  
healthy  controls  were  analysed  for  genotype  distribution  of   TCF7L2  gene. Association   
of  each  genotype  with  its  clinical  and  biochemical  parameters  were  studied.  
In  Master  table, the  characteristics  of   Type 2  Diabetes  Mellitus  patients [1 to 44]  
and  Control  group [45 to 88],  along  with  their  TCF7L2  genotyping  and  biochemical  
parameters  are  given. 
Statistical  analysis: 
• For  standard  statistical  analysis  of  the  data’s, Statistical  products  and  service  
solutions (SPSS)  package  were  used. 
• The  biochemical  parameters  between  type 2 diabetic  cases  and  healthy  controls  
were   tested  by  using  students  t  test . 
• The frequency  of   Genotype  distribution  between  cases  and  controls  were  
compared  by  using  Chi-square (χ
2 
)
  
test. 
• In  logistic  regression  analysis, Odds  ratio  with  two  tailed  p  values  and  95%  
confidence  intervals  (CI)  were  calculated. 
• Level  of  significance  for   p-value  was  set  at  point  < 0.05. If  p <0.001 shows  
strongly  significant.   
• Hardy- Weinberg  law  was  followed  and   the  frequency  of  genotype  were  tested  
for  Hardy – Weinberg  equilibrium.  
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Table -1: Comparison  of   age  between  cases and controls. 
Variables Group N Mean Std. Dev t-Value P-Value 
Age (years) 
Cases 44 49.75 8.535 
0.214 0.921 
Controls 44 45.23 8.364 
 
Table 1 : The  patients were with a mean age of  49.75 + 8.535 years,  while the controls were 
with a mean age of 45.23± 8.364 years. No Significant differences were observed between the 
mean ages of  patients and controls (p=0.921). 
 
Table – 2: Gender  distribution  among  cases  and  controls: 
Gender 
Group Chi-
Square 
Test 
P-Value 
Cases Controls Total 
 N % N % N % 
1 0.585 Male 20 45.5 20 45.5 40 45.5 
Female 24 54.5 24 54.5 48 54.5 
 
Table  2  shows   among  diabetic  cases, 20  were  males ( 45.5% ) and  24  were  females 
(54.5%). Among  controls, 20  were  males (45.5%)  and  24  were females (54.5%). No 
significant  difference  in  gender  distribution  between  cases  and  controls ( p = 0.585 ) was 
observed. 
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Table -1: Comparison  of   age  between  cases and controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table – 2: Gender  distribution  among  cases  and  controls: 
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Table 3:Comparison of  BMI  and  Waist  circumference  between  cases and controls: 
 
S.No Variables Group N Mean Std. Dev t-Value P-Value 
i. 
BMI 
Cases 44 25.52 4.717 
1.764 0.081 
Controls 44 27.06 3.348 
ii. 
Waist (cm) 
Cases 44 103.4 15.57 
4.186 <0.001 
Controls 44 94.5 8.15 
 
i.   Mean   BMI  of  cases  and  controls  were  25.52 + 4.717  and  27.06 + 3.348  
respectively, (p = 0.081). 
 
ii.   Mean   waist  circumference  of  cases  and  controls  were   103.4 + 15.57 and  94.5 
+ 8.15 cms. The  mean  value  of  cases  are  higher   than  controls  and  the  
difference  is  significant   with  p  value = <0.001. 
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Table 3:Comparison of  BMI  circumference  between cases and controls: 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3:Comparison of  Waist  circumference  between cases and controls: 
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Table 4: Comparison  of  Urea and  Creatinine  between  cases and controls: 
 
S.No Variables Group N Mean Std. Dev t-Value P-Value 
i. Urea 
(mg/dl) 
Cases 44 24.05 4.617 
1.321 0.190 
Controls 44 25.54 5.929 
ii. Creatinine 
(mg/dl) 
Cases 44 0.862 0.150 
3.179 0.002 
Controls 44 0.965 0.156 
 
i. The  mean  values  of  blood  Urea  in  cases  and  controls  were  24.05 +  4.617  and  
25.54 + 5.929  mg/dl  respectively  with   no  difference  in  Urea  levels  between  the  
study  groups   p = 0.190. 
ii. The  mean  value  of  creatinine  in  cases  were  0.862 + 0.150  and  controls  were  
0.965 +  0.156  mg/dl  and   shows  difference  in  creatinine  level  between  cases  
and  controls   with  a  p value =  0.002. 
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Table 4: Comparison  of Urea between cases and controls: 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Comparison  of Creatinine  between cases and controls: 
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Table  5: Comparison of  Glucose , HbA1c , Insulin and GLP-1  between cases and 
controls: 
S.No Variables Group N Mean Std. Dev t-Value P-Value 
i. Glucose 
(mg/dl) 
Cases 44 244.8 85.30 
10.211 <0.001 
Controls 44 108.6 23.50 
ii. 
HbA1C 
Cases 44 8.416 1.830 
11.363 <0.001 
Controls 44 5.218 0.371 
iii. Insulin 
(µIU/ml) 
Cases 44 276.0 332.4 
0.993 0.323 
Controls 44 211.2 277.6 
iv. GLP-1 
(pg/ml) 
Cases 44 0.101 2.353 
6.045 <0.001 
Controls 44 3.588 3.294 
 
 
i. The  mean   2  hours  postprandial   plasma  glucose  values   in  cases  and  controls  
are  244.8 mg/dl  + 85.30  and  108.6  mg/dl  + 23.50  respectively  (p < 0.001 ) . 
ii. The mean HbA1C values in cases  and  controls  are  8.416 ± 1.830 and  5.218 ± 
0.371  respectively ( p <0.001). 
iii. The  mean  value  of  insulin  in cases  and  controls  are  276.0 ± 332.4 and  211.2 ± 
277.6 µIU/ml  respectively( p = 0.323). 
iv. The  mean  value  of  GLP-1  measured  in  2 hours  post prandial  sample  in  cases  
and  controls  are  0.101 ± 2.353  and  3.588 ± 3.294  respectively   (p< 0.001) .  
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Table  5:Comparison of  Glucose between cases and controls: 
 
 
 
 
 
 
 
] 
 
 
Table  5:Comparison of  HbA1c  between cases and controls: 
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Table  5:Comparison of  Insulin between cases and controls: 
 
Table  5: Comparison of  GLP-1  between cases and controls: 
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Table  6: Comparing mean values of  postprandial lipid profile between cases and 
controls: 
 
 
i. The mean T.  Cholesterol   levels  in  cases  are   174.8 + 27.163  and  controls are 
169.8 + 20.564  mg/dl  (p = 0.990). 
ii. The  mean  HDL-c  level  in  cases are  43.78 + 8.770  mg/dl  and  in  controls are  
44.67  +  7.472  mg/dl (p = 0.510 ). 
iii. The  mean  Non-HDL –c  levels   in  cases   and  controls  are  131.1 + 25.547 mg/dl  
and  125.1 + 20.038 mg/dl  respectively  ( p = 1.220).   
 
 
 
 
 
 
Variables Group N Mean Std. Dev t-Value P-Value S.No Variables Group N Mean Std. Dev t-Value P-Value 
i. T.Cholesterol 
(mg/dl) 
Cases 44 174.8 27.163 
0.990 0.325 
Controls 44 169.8 20.564 
ii. HDL-c 
(mg/dl) 
Cases 44 43.78 8.770 
0.510 0.611 
Controls 44 44.67 7.472 
iii. 
NON-HDL 
Cases 44 131.1 25.547 
1.220 0.226 
Controls 44 125.1 20.038 
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Table 6: Comparing mean values of postprandial lipid profile in cases and controls: 
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Table -7 : Hardy-Weinberg equilibrium for Gene-1: rs7903146  ( cases  and  controls) 
 
Genotypes Observed # Expected # 
χ2 P value 
Homozygote reference: 59 61.4 
 
3.4249 
 
0.064 
Heterozygote: 29 24.2 
Homozygote variant: 0 2.4 
 
• In  the  study  population ,  the  genotype  frequency  are   CC – 59  ( 67%) ,  
CT -29  (33%)  , TT -0 (0%) .  
 
• By  Chi-square test , χ
2  
= 3.4249  and  p value  =  0.064 .  
 
• The  genotype  distribution  in  cases  and  controls  obeys  Hardy – Weinberg  
law  and  is  in  equilibrium. 
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Table 8: Genotype  distribution of  TCF7L2 gene at rs7903146 between  diabetic cases  
and controls : 
                
Gene-1: 
rs7903146 
Group 
Pearson 
Chi-Square 
test 
 Odds ratio                                      
      95% CI    P value 
Cases Controls Total  
 
32.145 
 
0.33 
[ 0.07 -1.56] 
 
 
   <0.001 
N % N % N % 
CC 17 38.6 42 95.5 59 67.0 
CT 27 61.4 2 4.5 29 33.0 
 
 
Frequency  of  genotype  distribution  between  cases  and  controls  are  as follows : 
• CC  genotype has a prevalence of  38.6% in  cases  as compared to 95.5% in 
controls. 
• CT  genotype  shows  61.4% prevalence in cases   and  4.5% in controls. 
• TT  genotype  frequency was not  detected in the study population.  
• χ
 2
 = 32.145, p<0.001. OR 0.33; 95%  CI (0.07-1.56).  
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Table 8: Genotype distribution of TCF7L2 gene at rs7903146 between diabetic cases and 
controls : 
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Table 9: Allele  distribution of  TCF7L2 gene at rs7903146 between  diabetic cases  and      
controls: 
Gene-1: 
rs7903146 
Group 
Chi-Square 
Test 
Odds ratio 
95% CI 
P-Value 
 
Cases Controls Total  
 
25.8 
 
 
0.19 (0.04-0.83) 
 
 
<0.001 
N % N % N % 
C 61 69.3 86 97.7 147 83.5 
T 27 30.7 2 2.3 29 16.5 
 
 
Frequency  of  allele  distribution  between  cases  and  controls  are  as follows : 
• C allele  frequency  in  controls   are (97.7% )  as compared  to cases (69.3%). 
• Prevalence of  T allele   in  cases is (30.7% )  and  in controls is (4.5%). 
• χ
2 
= 25.8, p<0.001, OR 0.19 ;95% CI (0.04-0.83). 
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Table 9: Allele distribution of  TCF7L2 gene at rs7903146 between  diabetic cases  and 
controls: 
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Table  10: Hardy-Weinberg equilibrium for Gene-2: rs12255372 (cases  and  controls). 
 
Genotypes Observed # Expected # 
χ2 P value 
Homozygote reference: 56 56.5 
0.1032 0.748 
Heterozygote: 29 28.0 
Homozygote variant: 3 3.5 
   
• In  the  study  population ,  the  genotype  frequencies  are   GG – 56 (63.6%) , GT -29 
(33%)  and  TT -3 (3.4%). 
• By  Chi-square test, χ
2  
= 0.1032  and  p value  =  0.748.  
• The  genotype  distribution  in  cases  and  controls  obeys  Hardy – Weinberg  law  
and  is  in  equilibrium. 
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Table11: Genotype  distribution  of  TCF7L2  gene  at   rs12255372  between  cases  and  
control: 
 
Gene-2: 
rs12255372 
Group 
N % 
Odds  ratio 
95% CI 
Chi-Square Test  
P-Value 
Cases Controls  
reference 
 
4.299 
 
0.112 GG 24  (54.5%) 32   (72.7%) 
GT 19  (43.2%) 10   (22.7%) 2.53 [1.01-6.42] 
TT 1     (2.3%) 2  (4.5%) 0.67 [ 0.06-7.79] 
 
Frequency  of  genotype  distribution  between  cases  and  controls  are  as follows : 
• GG  genotype has a prevalence of  54.5%  in  Cases  as compared to 72.7% in controls. 
• GT  genotype  shows  43.2% prevalence in cases   and  22.7% in controls  OR-2.53; 
95%CI [1.01-6.42]. 
• TT  genotype  frequency  is 2.3% in cases as compared to 4.5% in controls, OR-0.67; 
95%CI [ 0.06-7.79].  
•  χ
2
 = 4.299, p=0.112.  
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Table11: Genotype distribution  of  TCF7L2  gene  at   rs12255372 between  cases  and 
control: 
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Table12 : Allele  distribution  of  TCF7L2  gene  at   rs12255372  between  cases  and 
control: 
 
Gene-2: 
rs12255372 
Group  N % Odds  ratio 95% CI Chi-
Square 
Test 
 
P-Value 
cases controls 
G 67   (76.1%) 74  (84.1%) 
1.66 [0.78-3.53] 1.748 0.093 
T 21  (23.9%) 14  (15.9%) 
 
 
Frequency  of  allele  distribution  between  cases  and  controls  are  as follows : 
• G  allele  frequency   in  controls  is (84.1% )  as compared  to cases (76.1%). 
• Prevalence of  T allele    in  cases (23.9% )  and  in controls (15.9%) . 
• χ
2 
= 1.748, p=0.093, OR 1.66; 95% CI (0.78-3.53). 
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Table 12: Allele  distribution of  TCF7L2 gene at  rs12255372 between  cases  and 
control: 
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DISCUSSION 
 
               In  this  study, we have evaluated  the  association  of  TCF7L2  gene  polymorphism 
with  Type  2 Diabetes  among 44 cases  and 44 controls in  Chennai  suburban  population. 
We  have  also  attempted  to  evaluate  the  effect  of  gene  polymorphism  on  GLP-1  and  
Insulin levels  in  the  postprandial  sample  of  age  and  gender  matched  study  population. 
 
The transcription factor TCF7L2 plays a key role in  Wnt signaling pathway .TCF7L2 
gene  spans  nearly 215.9Kbp containing 17 exons situated  in high mobility group box. Wnt 
signaling is essential for glucose and lipid metabolism, functioning and proliferation of beta-
cells of pancreas and GLP-1, the incretin hormone production
(113)
. Wnt activity is important 
particularly, for GLP-1 secretion in intestinal endocrine L-cells
(113)
. Any dysfunction in this 
pathway may lead to reduced GLP-1 secretion which may have effect on insulin secretion. 
Thus, GLP-1 plays a critical role in blood glucose homeostasis through insulin. The  increased  
risk  of  T2DM  conferred  by  variants  in  TCF7L2 involves  the  enteroinsular  axis , 
impaired  GLP-1  secretion  and  enhanced   hepatic  glucose  production. The expression of 
TCF7L2 gene variants may dysregulate transcription of proglucagon gene that impairs GLP-1 
secretion. This altered enteroinsular axis affects second phase of insulin secretion 
significantly. Reduced insulin secretion along with insulin resistance enhances hepatic glucose 
production leading to chronic hyperglycemic status. 
 
It has been postulated that TCF7L2 gene polymorphism may confer susceptibility to 
T2DM by indirectly altering GLP-1 levels
(114)
. It was foreseen that in TCF7L2 risk allele 
carriers, the Wnt signaling is potentially increased in adipose tissue leading to 
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undifferentiation, impared  growth and development of  pre-adipocytes , that may influence 
BMI and waist circumference with its attendant  sequelae
(114,115)
.Thus, TCF7L2 might affect 
adipogenesis in peripheral tissues leading to insulin resistance
(117)
. 
 
The results in our study are similar to earlier findings that were done in 
Indian
(25,113,116,
)as well as non-Indian population
(108,118-130)
.It shows a strong association of 
TCF7L2 variant  with T2DM.  This study not only restated the association of TCF7L2 with 
T2DM but also  its effect  on  gene product   ,GLP-1 and Insulin . GLP-1 levels are reduced in 
risk genotype carriers. 
Thus our study reiterates TCF7L2 as the most important T2DM susceptible gene in our 
study population which has been universally replicated. Of the two SNPs, rs7903146 is 
significantly associated with T2DM which is consistent with other studies in Indian 
population
(25,113,116,131-133)
 as well as in migrant  Indian  population
(134)
. Although the frequency 
of T allele  in our  study population was similar to frequency  in Chandak et al
(116)
, there is a 
lower frequency of T allele  in diabetic  subjects  of  our population  than that reported in 
western Indian population
(116)
.  
In our study the TCF7L2 variant at rs12255372 did not show association with T2DM 
and the results are consistent with studies done by Uma Jyothi et al, in south Indian population 
where this variant  at rs12255372 shows reduced risk compared  to other sites
(113)
. T allele  did 
not show any difference between cases and controls  in our study which is in accordance with 
study by Mohan et al,  where T allele  frequency  at rs12255372  is less in cases  as compared  
to its frequency in controls
(25,113)
. 
Various  studies  that  predicted  the  strong  association  of  TCF7L2  gene  
polymorphism  at  rs7903146  and  type 2 diabetes are.  
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• Grant  et  al., 2006; demonstrated  a  strong  association  in  Icelandic  population 
.Compared with non-carriers, heterozygous and homozygous carriers of the at-risk 
alleles (38% and 7% of the population, respectively) have relative risks of 1.45 and 
2.41. In  Icelandic cohort  P = 2.1  10-9 .This was replicated in a Danish cohort (P = 
4.8  10-3) and in a US cohort (P = 3.3  10-9
(108)
. 
• Groves  et  al., 2006; replicated  the  association  in  UK  population. 
• Damcott et  al .,2006;  replicated  the  association  in  Amish  population.  They  
established  a  strong  association  of  TCF7L2  gene  polymorphism  at  rs7901695 
and rs7903146 (P = 0.008–0.01; OR 1.53–1.57) and marginal association with 
rs11196205 and rs12255372 (P = 0.07 and P = 0.04, respectively) with  Type  2  
Diabetes  in  Amish  population.
(65)
 
• Scott et al.,2006; replicated  in   French  population. Both the T-allele of rs7903146 
and the T-allele of rs12255372 significantly increase Type 2 Diabetes risk with an 
allelic odds ratio (OR) of 1.69 (95% CI 1.55–1.83) (P = 6.0 × 10−35) and 1.60 (1.47–
1.74) (P = 7.6 × 10−28), respectively
(136)
. 
• In  Chinese  population   association  of  TCF7L2  gene polymorphism  at  rs7903146 
,T allele was associated with an increased risk for T2DM under a dominant model, a 
co-dominant model and an allele contrast model, with an OR of 1.54 (1.32, 1.79), an 
OR of 1.53 (1.31, 1.79) and an OR of 1.52 (1.31, 1.76), respectively. The rs290487 C 
allele showed no significant overall association with T2DM, yielding ORs of 1.08 
(0.88, 1.32) under a dominant model, with strong evidence of heterogeneity
(135)
 
• In  India , a  study was  conducted  in  Hyderabad , the  diabetic  capital  of  India  .It is 
a case-control study of the three SNPs of TCF7L2, rs7903146, rs12255372 and 
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rs11196205, genotyped on Sequenom Massarray platform, in a sample of 758 patients 
and 621 controls.  The greatest risk of developing the disease was conferred by 
rs7903146, implicating susceptibility for diabetes (p<0.01)
(113)
. 
• In Chennai , the  study  on  TCF7L2  gene polymorphism  show, T allele of the 
rs12255372(G/T) and rs7903146(C/T)  confer  more  susceptibility to type 2 diabetes 
mellitus in Asian Indian
(25)
. 
 
GLP-1 the incretin hormone which is the gene product of TCF7L2 shows significantly 
reduced  levels in  2-hour postprandial sample in type 2 diabetic cases than controls ,further 
strengthens our finding that the CT genotype  of  TCF7L2 variant at rs7903146, is a risk 
genotype for type 2 diabetes mellitus. This finding is against the reports done in German study 
population
(137)
. 
In our study, 2-hour postprandial  insulin levels did not show difference between cases 
and controls  This  might be due to relatively small size of the study population and other 
interfering mechanisms from insulin anabolism to catabolism that alters insulin level  which is 
in accordance with the study done in Spanish population  where the 2-hours postprandial 
insulin level did not show any difference but  proinsulin to insulin ratio  was higher in risk 
genotype carrying  T2DM cases than controls
(138)
. Though the exact  mechanism of TCF7L2 
gene is not known, it was  postulated  that  TCF7L2 gene polymorphic variants  have  effect 
on  proinsulin  processing in the beta cells of pancreas  that may predispose to type 2 
diabetes
(138)
. 
 CT genotype T2DM cases had  high 2-hour plasma glucose levels and this further 
strengthens  our study findings that T allele at rs7903146  is a risk allele for type 2 diabetes. 
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This finding is  similar to studies by Chandak et al
(116)
 and Lehman et al
(139)
  who also reported 
increased 2-hour plasma glucose level in subjects with rs7903146 variants.  
                  The postprandial lipid profile did not show any difference between diabetic group 
and control group. The fasting lipid profile was also not significantly different in similar 
studies among Indian population 
(113)
. Recent studies indicate that for the cardiovascular risk 
assessment in T2DM, postprandial lipid profile could identify the risk factors better than 
fasting lipid profile
(140)
. In the cardiovascular risk assessment in Type 2 DM subjects, it is 
important to routinely estimate the postprandial lipid profile, in addition to the fasting lipid 
parameters. Atherosclerosis is a postprandial phenomenon with respect to lipids, as we are in 
the postprandial phase for most of the day, with an additional adverse effect of the meal 
induced hyperglycaemia. Also the total cholesterol, TGL and LDL levels were elevated in 
postprandial state as compared to fasting state in T2DM also HDL levels were lower in 
postprandial  than in fasting. Rectifying the abnormal postprandial lipid parameters early in 
the course of diabetes, we can prevent the hazardous complications which are associated with 
Type 2 DM, the most common one being atherosclerotic coronary artery disease. 
             Despite the promising evidence for the association of TCF7L2 gene polymorphism at 
rs7903146 with Type 2 Diabetes, the precise mechanism behind TCF7L2 SNPs, which are 
identified in the intronic regions, is still unclear. It is a must to elude the mechanism of 
intronic SNPs that affect the expression of TCF7L2.Earlier studies showed the expression of 
TCF7L2 in gut than pancreatic islets. Henceforth, more research is focused on functional 
significance of this gene and more evidences are needed to study if TCF7L2 variants leads to 
alternative splicing and   gene expression or change in protein structure. 
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         It is essential to assess the role of different genes in the cause for Type 2 Diabetes in  
Chennai, other regions of Tamilnadu  and India which has high prevalence of T2DM. This 
gauges enormous ethnic, geographic, genetic and cultural  heterogeneity  in the risk genetic 
profile of the Indian population. In conclusion, our study reaffirms the association of 
rs7903146 polymorphism of the TCF7L2 gene with T2DM in the Chennai suburban 
population in southern India.  
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SUMMARY 
 
In  Type 2 Diabetes,  although  there  is  considerable  debate  as  to  the  relative  
contributions  of  beta-cell  dysfunction  and  reduced  insulin  sensitivity  to  its  pathogenesis,  
both  these  factors  play  important  roles. But  the  mechanisms  controlling  the  interplay  of  
these  two   defects  are  unclear. A number of factors   and mechanisms have been  suggested  
till  date.  
Production and secretion of insulin from the β-cells of the pancreas is very crucial in 
maintaining normal glucose level. This is achieved by tight regulation of insulin synthesis and 
exocytosis from the β-cells in response to changes in blood glucose levels and incretin  
hormones specifically by GLP-1  and   the regulation  is at transcriptional, post-transcriptional 
and  post-translational  levels.  The incretin GLP-1 is an insulinotropic hormone that 
potentially affect blood insulin level in the postprandial state. Through Wnt signaling, 
TCF7L2 the main transcription factor plays an important  role in glucose induced  - insulin 
gene transcription and pancreatic β-cell function. 
TCF7L2  is  the  only transcription  factor  with  the  strongest  effect  on  type 2 
diabetes  identified  to  date.  But  the  molecular  mechanism  as  to  how  variation  in  the  
gene  increases  the  risk  remains  elusive. The  phenotype  changes  associated  with  the  risk  
genotype  suggest  that  TCF7L2  polymorphism  affect  several  vital  functions  leading  to  
impaired  pancreatic  islet function  and  reduced  islet  mass , through GLP-1 and  also  
directly  that  manifests  as  Type 2 Diabetes mellitus. 
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The  gene  expression of  TCF7L2  variants ,  was  found  to  exhibit  an  upregulation  
of  mRNA levels  and  down  regulation  of  protein  level  in  specific  cells
(141)
.TCF7L2  ,a 
Wnt signaling – associated  transcription  factor  is  expressed  in  several  tissues, including  
Gut  and  pancreas. Since 2006, the  strong  association  of  single  nucleotide  polymorphisms  
in  the  TCF7L2  gene at  rs7903146  and  rs  12255372  that  are  located  between  exons  3  
and 4 and exons 4 and 5, respectively with type 2 diabetes has been confirmed in numerous  
studies
(108,142,145)
 . 
The  presence  of  risk  alleles  in  TCF7L2   gene  are  associated  with  specific  
T2DM  phenotypes  characterized  by 
• early  impairment  of  beta- cell  function,   
• a  reduction  in  GLP-1  induced  potentiation of  insulin  secretion 
• fasting  and  postprandial  hyperglycemia  in  prediabetics 
(144,145)
. 
This study,  done  on 44 type 2 diabetic  cases  and  44  healthy  controls,  who  were  
age  and  gender  matched  ,to  see the  association  of  TCF7L2 gene  polymorphism  and  ty 2 
DM, revealed: 
1. For  rs7903146  (C/T)  polymorphism,  
• There  is  an  increased  frequency  of  risk  allele “ T” in cases  ( 30.7%)  than  
controls (2.3%) with  a p<0.001.  
• The  GLP-1  level  is  reduced  in  both  cases  and  controls  with  risk  genotype  CT  
when  compared  to  subjects  with CC genotype. 
• The  Insulin  level  show  a  significant  difference   between  cases   and  controls  
with  CT  genotype .  
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• Presence  of  risk  T allele  coincides  with  hyperglycemic  status  in  both  cases  and  
controls.    
2. At  rs 12255372 (G/T)  polymorphism,   
There is  no  significant  increase  in  risk  “T”  allele   distribution  among  cases  and  
controls  p=0.093.  
Our  study  revealed  a  strong  association  of  TCF7L2  gene polymorphism  at  
rs7903146  with  Type 2 Diabetes.   
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                                                              CONCLUSION 
 
 
From the above discussion with regard to the results of the study, the conclusions  
arrived  at are: 
• TCF7L2  gene  polymorphism  at  rs7903146   is  strongly  associated  with  type 2 
diabetic  patients  in  Chennai  suburban  population, 
• The  risk  allele   “T”  and  genotype “ CT”   is  more  commonly  associated  with  
diabetic  cases  than  healthy  controls. 
• GLP-1  level  is  reduced  in  subjects  with  CT  genotype  than  those  with  CC  
genotype  in  the  study  population , showing  the  effect  of  TCF7L2  gene  
polymorphism  on  GLP-1  production. 
• CT  genotype is associated with Postprandial  hyperglycemic  status than  CC 
genotype    in  study  subjects which emphasizes the role of  TCF7L2 in maintaining 
blood glucose level. 
• TCF7L2  gene  polymorphism  at  rs 12255372  does  not  show  significant  
association with  type  2  diabetic  patients  in  Chennai  suburban  population . This  
differs  from  previous  studies  in  Chennai,  mandating  large  study  groups  in  this  
study  area  to  assess  the  frequency  of  distribution  for  TCF7L2  gene  
polymorphism-  rs12255372 . 
 
The  increased  risk  of  T2DM  conferred  by  variants  in  TCF7L2 involves  the  
enteroinsular  axis , impaired  GLP-1  secretion  and  enhanced   hepatic  glucose  production. 
. 
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LIMITATIONS 
 
This study with the population of 88 subjects had 44 diabetics as cases and 44 age and 
gender matched apparently normal subjects as controls, was done to look for an association of 
TCF7L2 gene polymorphism in Type 2 Diabetes. 
Though the study revealed a strong association of TCF7L2 gene polymorphism at 
rs7903146, there was no significant association at rs12255372. This could be still due to lack 
of adequate samples where in all genotypic variants may not be included. To confirm the lack 
of association the study needs to be replicated in a large sample so as to include all the genetic 
variants. Only this can aid in documenting the lack of association at rs12255372 being true. 
To look for the effect of polymorphism in blood glucose homeostasis, it would have 
been better if 1-hour post meal insulin and GLP-1 levels were measured, as the effect of 
incretin is to increase the second phase of insulin secretion. 
Additionally, Proinsulin to insulin ratio gives an insight into the processing of insulin 
from its precursor for which the effect of GLP-1 is essential. This needs to be done in 2-hour 
post meal sample. 
To document the effect of TCF7L2 gene polymorphism and its role in blood glucose 
homeostasis, assessment of insulin should be done in fasting,1-hour post meal and 2-hour post 
meal samples which emphasis the facts of basal insulin secretion ,the effect of incretin in 
increasing the second phase of insulin secretion and processing of insulin from its precursor 
recpectively. 
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 Lipid profile diagnostically is always done in a fasting sample to assess the 
cardiovascular risk in T2DM patients. Recent studies have revealed that a postprandial sample 
is better for risk assessment as atherosclerosis is a postprandial phenomenon and we are in the 
postprandial state for most of the day. But the lack of reference values for postprandial lipid 
levels hinders the interpratation of lipid levels in T2DM patients for risk assessment. Hence it 
would have been better if the lipid profile was assayed in both the fasting and postprandial 
states. 
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SCOPE FOR FURTHER STUDY 
 
Further studies are eagerly needed, to  translate  the  GWAS (Genome Wide Associatio  
Study)   data  to clinical interpretations. The regulation of TCF7L2 variants and the functional 
consequences at the protein level are still poorly understood. A clear picture of the molecular 
mechanism will be necessary to understand how an intronic variation in TCF7L2 can 
influence islet function. 
TCF7L2  polymorphism  leads  to  various  splice  variants  which  are  differently  
regulated  on  the  post-transcriptional  level  and  would  encode  less active  isoforms  
showing  different  action  on  beta-cell  function and  survival.  
• Quantitative assessment of  TCF7L2 and its correlation with GLP-1 levels would better 
help to identify the association of TCF7L2 polymorphism and its influence on protein 
levels.  
• Due  to  TCF7L2  polymorphism ,if  GLP-1  level  is  altered  needs  further  studies.   
• Action  of  TCF7L2  gene  in  adipose  tissue  and  its  role  in  lipid  metabolism  needs  
further  research. 
• Measurement of GLP-1 and Insulin in 1 hour postprandial sample documents the effect of 
incretin on the second phase of insulin secretion. 
• Proinsulin to insulin  ratio measurement aids in understanding the effect of GLP-1 on 
insulin processing.   
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TCF7L2  gene  involved in   regulating  glucose  homeostasis  needs further 
exploration .  This may aid  in  genetic  diagnosis  and  early  prevention  of  Type  2  
Diabetes. TCF7L2  shows  the  largest  effective  size  with  an  odds  ratio (OR) of  1.37,  
followed  by   KCNQ1 with  second  largest  effective  size with  OR of  1.29 (Yasuda et al., 
2008; Unoki et al., 2008). However the molecular mechanism by which they exert their 
biological functions is still not known. So, further association studies for TCF7L2and KCNQ1 
and other variants are needed to assess their role in other populations, especially populations 
with a high prevalence of Type 2 Diabetes such as in India. 
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PROFORMA 
 
Name :      Age:          M/F                                                                                              
OP/IP no :                                                  Address :                                                                 
Occupation: 
 Presenting Complaints:  
Past H/O:      
DM / HT/ Hypercholestrolemia/  Hypothyroid/  IHD/ Endocrine Disorder/ Renal Disease/ 
Hepatic  Disease. 
Treatment H/O:  [exclusions-on insulin,GLP1 analogs ]  
Drug- single/ combination  
Personal  H/O:  smoking /alcohol/tobacco chewing 
Family  H/o: 
O/E:  
Built -  obese/thin/moderate              BMI:   
Height-               Weight-                       Waist-            
Pedal edema /Anemia / Lymphadenopathy-      
Vitals:    
 BP:                          Pulse Rate: 
 Systemic examination:  
 CVS:                                        RS:                                        
 CNS:                                       Abdomen:                                    
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 Diagnosis:                       
                   
Investigations: 
Blood sugar –  
Sr.Urea  : 
Sr. Creatinine: 
T.Cholestrol: 
HDLc: (Direct)  
Non-HDLc : (calculated) 
HbA1C: 
Insulin: 
GLP-1: 
TCF7L2 Gene Polymorphism:     rs 7903146-   CC / CT / TT 
                                                    rs 12255372-  GG /GT / TT 
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ABBREVIATION 
 
ADA- American Diabetes Association 
WHO-World Health Organization  
GWAS-Genome Wide Association Studies 
IDF-International  Diabetes  Federation 
NGSP- National  Glycohemoglobin  Standardisation  Program  
 DCCT- Diabetic  Control  and  Complications  Trial   
GLP- Glucose - dependent  Insulinotropic  Polypeptide 
GLP-1- Glucagon - Like  Peptide-1 
NGT- Normal  Glucose  Tolerance    
PGDP-Pro-Glucagon  Derived  Peptide 
 GRPP- Glicentin – Related  Pancreatic  Polypeptide    
MPGF- Major  Proglucagon  Fragment  
PC- Prohormone  convertase   
GEFII -  Guanine  nucleotide  Exchange  Factor II  
CIE -  Ca
2+
 dependant   Insulin  Exocytosis   
cAMP- cyclic  Adenosine  Mono Phosphate   
PKA- Protein  Kinase  A  
PG - Pro-Glucagon fragment  
IP-1 - Intervening  Peptide-1 
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IP-2 - Intervening  Peptide-2 
gcg  - glucagon gene 
LRP - Lipoprotein  Receptor-related  Protein  
Ryk - Receptor  tyrosine  kinase  
Dsh/Dvl - Dishevelled  
HMG - High  Mobility  Group  box  
TLE - Transducin-like Enhancer 
TCF7L2 -Transcription  factor  7 – like 2 
CtBP-1  - C-terminal  binding  protein-1   
SNP – Single Nucleotide Polymorphism 
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